Study Title MATRIX -002:  Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal 
Films  
Protocol Version V1.[ADDRESS_846554]  Number : [STUDY_ID_REMOVED]  
Document Date:  24May2023  
 
 
MATRIX -002 
 
Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal 
Films  
 
 
MATRIX: A [LOCATION_003]ID Project to Advance the Research and Development of Innovative 
HIV Prevention Products for Women 
 
 
Funding Agenc y: 
US Agency for International Development ([LOCATION_003]ID)  
  
 
Award/Grant Number(s) : 
Cooperative Agreement # 7200AA22CA00002  
  
 
 
A Non-IND S tudy  
 
 
 
Pharmaceutical Collaborator : 
University of Pi[INVESTIGATOR_9109] (Pi[INVESTIGATOR_32887])  / Magee-Womens Research Institute and Foundation 
(MWRIF)  
  
 
Protocol C o-Chair:  
Nyaradzo M. Mgodi, MBChB, M Med 
 
 
Protocol Co- Chair:  
Alexandra Minnis, PhD  
   
Version 1.[ADDRESS_846555] OF ABBREVIATIONS AND ACRONYMS  ...........................................................................  v 
PROTOCOL TEAM ROSTER .................................................................................................. vii 
INVESTIGATOR SIGNATURE [CONTACT_166920] ..................................................................................... xvi 
PROTOCOL SUMMARY  .......................................................................................................  xvii 
1 KEY ROLES  ............................................................................................................ 1 
1.1 Protocol Identification  ............................................................................................ 1 
1.2 Funding Agency and Monitor Identification  .............................................................. 1 
1.3 Laboratory(ies) ...................................................................................................... [ADDRESS_846556] Formulation and Storage  ................................................................  12 
6.4 Supply and Accountability  ....................................................................................  13 
6.5 Ancillary Study Supplies  .......................................................................................  13 
6.6 Concomitant Medications  ..................................................................................... 13 
6.7 Prohibited Medications, Products and Practices  ......................................................  13 
 
 
MATRIX -002, Version 1.0          24 May 2023 iii 7 STUDY PROCEDURES  ...........................................................................................  14 
7.1 Screening Visit .....................................................................................................  14 
7.2 Enrollment Visit – Visit 2 (Day 0)  .......................................................................... 15 
7.3 Follow -up Visits/Contacts  ..................................................................................... [ADDRESS_846557]  . 22 
7.5 Interim Visits/Contacts  .........................................................................................  [ADDRESS_846558]  ............................ 32 
9.4 Permanent Discontinuation in Response to Observed Adverse Events  ..................... 32 
9.5 Other Clinical Findings  .........................................................................................  32 
9.6 HIV Infection .......................................................................................................  33 
9.7 Pregnancy ...........................................................................................................  33 
9.8 Criteria for Early Termination of Study Participation  ............................................... 33 
1
0 STATISTICAL CONSIDERATIONS  .......................................................................... 34 
10.1 Overview and Summary of Design  ........................................................................ 34 
10.2 Study Endpoints  .................................................................................................. 34 
10.3 Sample Size and Power Calculations  .....................................................................  35 
10.4 Randomization Procedures  ................................................................................... 36 
10.5 Participant Accrual, Follow -up and Retention  .........................................................  36 
10.6 Data and Safety Monitoring and Analysis  ...............................................................  36 
11 DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645]  .............................................................. 38 
11.1 Data Management Responsibilities  ........................................................................ 38 
11.2 Source Documents and Access to Source Data/Documents  .....................................  39 
11.3 Quality Control and Quality Assurance ...................................................................  39 
12 CLINICAL SITE MONITORING  ............................................................................... 39 
13 HUMAN SUBJECTS PROTECTIONS  ........................................................................ 40 
13.1 Institutional Review Boards/Ethics Committees  ......................................................  40 
13.2 Protocol Implementation  ......................................................................................  41 
13.3 Study Coordination  .............................................................................................. 41 
13.4 Risk Benefit Statement  .........................................................................................  42 
13.5 Informed Consent Process  ................................................................................... 43 
13.6 Participant Confidentiality  ..................................................................................... 44 
 
 
MATRIX -002, Version 1.0          24 May 2023 iv 13.7 Special Populations  .............................................................................................. 44 
13.8 Compensation  .....................................................................................................  45 
13.9 Reporting  ............................................................................................................ 45 
13.10  Access to HIV -related Care  ................................................................................... 45 
13.11  Study Discontinuation  .......................................................................................... 46 
14 PUBLICATION POLICY  .........................................................................................  46 
15 APPENDICES  .......................................................................................................  46 
APPENDIX I:  SCHEDULE OF STUDY VISITS AND EVALUATIONS ........................................... 47 
APPENDIX II:  ALGORITHM FOR HIV TESTING – SCREENING/ENROLLING/FOLLOW-UP .........  49 
APPENDIX III:  SAMPLE INFORMED CONSENT FORM (SCREENING, ENROLLMENT, LONG -TERM 
STORAGE AND FUTURE TESTING)  ......................................................................................  50 
APPENDIX IV:  SAMPLE INFORMED CONSENT FORM (SEXUAL PARTNER SUBSET)  ................. [ADDRESS_846559]  OF FIGUR ES 
  
FIGURE 1: STUDY VISIT SCHEDULE  ................................................................................  XVIII 
FIGURE 2: STUDY PRODUCT REGIMEN  ............................................................................... 12 
FIGURE 3: STUDY VISIT SCHEDULE  ....................................................................................  [ADDRESS_846560] OF TABLES  
  
TABLE 1: SCREENING VISIT  ...............................................................................................  15 
TABLE 2: ENROLLMENT VISIT – VISIT 2 (DAY 0)  ................................................................ . 16 
TABLE 3:  PHONE CHECK- IN ([ADDRESS_846561] INSERTION) – VISIT 3  ......................  17 
TABLE 4: 1 -WEEK AND 2 -WEEK TELEPHONE CONTACTS – VISITS 4 AND 5 (7 AND 14 DAYS 
AFTER VISIT 2)  .......................................................................................................... 17 
TABLE 5: 4 -WEEK VISIT – VISIT 6 (28 DAYS AFTER VISIT 2) ............................................... 18 
TABLE 6:  PHONE CHECK- IN (24 -72 HOURS AFTER 2ND INSERTION) – VISIT 7  ....................  19 
TABLE 7: [ADDRESS_846562] – VISIT 8 (14 DAYS AFTER VISIT 6)  ......................  20 
TABLE 8: 8 -WEEK VISIT – VISIT 9 (28 DAYS AFTER VISIT 6) ............................................... 20 
TABLE 9: FINAL CONTACT/SEV – VISIT 10 (7 DAYS AFTER VISIT 9)  .....................................  21 
TABLE 10: IDI VISIT WITH SEXUAL PARTNER SUBSET  ........................................................  22 
TABLE 11 : SUMMARY OF BEHAVIORAL ASSESSMENTS  .........................................................  24 
TABLE 12: RANGE OF POTENTIAL EFFECT SIZES FOR EACH ENDPOINT  . ..............................  [ADDRESS_846563]  
CBC  Complete blood count  
CDC  Centers for Disease Control and Prevention  (US) 
CDM  Clinical data manager  
CFR  Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Act  
CQA  Critical quality attributes  
CRF  Case report form  
CRM  Clinical research manager  
CRS  Clinical research site  
CT  Chlamydia trachomatis  
CV  Cervicovaginal 
CVF  Cervicovaginal fluid  
DAIDS   Division of AIDS  
DRA  Drug regulatory authority 
ECS-HSR Education and Compliance Support for Human Subject Research  
FDA  U.S. Food and Drug Administration  
GC  Neisseria gonorrhea  
GCP  Good Clinical Practice  
GDP  Good Documentation Practices  
GMP  Good Manufacturing Practice  
GRAS   Generally regarded as safe  
HHRC   Harare Health and Research Consortium 
HIPAA   Health Insurance Portability and Accountability Act  
HIV  Human Immunodeficiency Virus  
IATA  International Air Transport Association  
ICH E6  International Conference for Harmonization Guideline for Good Clinical Practice  
IDI  In-depth interview  
IEC  Independent Ethics Committee  
IND  Investigational New Drug 
IoR  Investigator of Record  
IRB  Institutional Review Board 
ISP  Independent Safety Physician  
IUD  Intrauterine device  
 
 
MATRIX -002, Version 1.0          24 May 2023 vi KEMRI   Kenya Medical Research I nstitute  
KOH  Saline/potassium hydroxide  
LDMS  Laboratory Data Management System 
LTFU  Loss-to-follow -up 
MWRIF  Magee- Womens Research Institute and Foundation  
NAAT   Nucleic acid amplification test  
NIH  National Institutes of Health  
OHRP   Office for Human Research Protections  
PEP  Post-exposure prophylaxis  
PHI  P rotected health information  
PI  [INVESTIGATOR_632043]  P elvic inflammatory disease  
PrEP  Pre- exposure prophylaxis  
PSRT  Protocol Safety Review Team  
PTID  P articipant identifier  
QA  Quality assurance  
QC  Quality control 
RTI  Reproductive tract infection  
SAE  Serious adverse event  
SEV  Study Exit Visit 
SMS  Short message service  
SOP  Standard operating procedures  
SSA  Sub- Saharan Africa  
SSP  Study specific procedures  
STI  Sexually transmitted infection  
UPT  Urine pregnancy test  
[LOCATION_003]ID  US Agency for International Development  
UTI  Urinary tract infection  
VALUE  Vaginal film as A Low -cost, User -administered, and Extended -release product  
Wits RHI  Wits Reproductive Health and HIV Institute  
 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 vii MATRIX -002 
 
Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal 
Films  
PROTOCOL TEAM ROSTER  
 
 
Protocol C o-Chair  
 
Nyaradzo M. Mgodi, MBChB, M Med 
Protocol Co- Chair  
Zengeza Clinical Research Site (CRS)  
[ADDRESS_846564]  
Zengeza 3 Clinic  
Chitungwiza, Zimbabwe  
Phone: +263 -772-264616 
Email: nm godi@uz- ctrc.org  
 
 Protocol Co- Chair  
 
Alexandra Minnis, PhD  
Protocol Co- Chair  
RTI International 
[ADDRESS_846565]  
Berkeley, CA [ZIP_CODE] [LOCATION_003]  
Phone: [PHONE_13199] 
Email: [EMAIL_12086] 
 
  
 
 
MATRIX -002, Version 1.0          24 May 2023 viii Clinical Research S ite (CRS) Investigators  
  
University of Pi[INVESTIGATOR_9109] (Pi[INVESTIGATOR_32887])/Magee -Womens Research Institute and Foundation 
(MWRIF)  CRS 
 
Katherine Bunge, MD, MPH  
Site Investigator of Record  
Department of Obstetrics, Gynecology and Reproductive Sciences  
University of Pi[INVESTIGATOR_99601]  
[ADDRESS_846566]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003] 
Phone: 412- 641-6967 
Fax: 412 -641-1133 
Email: [EMAIL_4599]  
 I
ngrid Macio, PA-C 
Site Investigator  
Department of Obstetrics, Gynecology and Reproductive Sciences  
University of Pi[INVESTIGATOR_99601]  
[ADDRESS_846567]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003] 
Phone: 412- 641-4242 
Fax: 412 -641-2319 
Email: [EMAIL_12087]  
 
 
Harare Health and Research Consortium (HHRC ) CRS 
 
Nyaradzo M. Mgodi, MBChB, M Med 
Site Investigator of Record  
Zengeza CRS  
[ADDRESS_846568]  
Zengeza 3 Clinic  
Chitungwiza, Zimbabwe  
Phone: +263 -772-264616 
Email: nmgodi@uz- ctrc.org  
   
 
  
 
 
MATRIX -002, Version 1.[ADDRESS_846569] Province  
South Africa 2571  
Phone: [PHONE_13208]  
Fax: [PHONE_13209]  
Email: p [EMAIL_12088]  
 Heeran Makkan, MSc 
Site Investigator  
Tembisa  CRS 
Corner Rev RTJ Namane and Flint Mazibuko Drive  
Tembisa Hospi[INVESTIGATOR_307], Hospi[INVESTIGATOR_633946], Tembisa 
Johannesburg, Gauteng  
South Africa 1632  
Phone: [PHONE_13210]  
Email: h [EMAIL_12089] 
 
 
Wits Reproductive Health and HIV Institute (Wits RHI)  CRS 
 
Thesla Palanee -Phillips, MMedSci, PhD, MSc  
Site Investigator  
Wits RHI Research Centre  
[ADDRESS_846570]-5th Floors  
Hillbrow, Johannesburg  
South Africa 2038  
Phone: [PHONE_13211]  
Fax: [PHONE_13212]   
Email: [EMAIL_12090]    
 
Nkosiphile Ndlovu, MBChB, HIV Dip Man (SA)  
Site Investigator of Record  
Wits RHI Research Centre  
[ADDRESS_846571]-5th Floors  
Hillbrow, Johannesburg  
South Africa 2038  
Phone: [PHONE_13213]  
Email: [EMAIL_12091]    
   
 
 
MATRIX -002, Version 1.0          24 May 2023 x Kenya Medical Research Institute (KEMRI) CRS  
 
Kenneth Ngure, PhD  
Site Investigator  
Jomo Kenyatta University of Agriculture and Technology (JKUAT) -College of Health Sciences  
[PO_BOX]- [ZIP_CODE]  
Nairobi, Kenya  
Phone: 254- 722362219  
Email: K ngure@ pi[INVESTIGATOR_633947].org   
 
Nelly Rwamba Mugo, MBChB, M Med, MPH  
Site Investigator of Record  Kenya Medical Research Institute (KEMRI) 
OAU Road   
Thika , Kenya  
Phone: 254- 733629665  
Email: [EMAIL_12092]  
 
  
 
 
MATRIX -002, Version 1.0          24 May 2023 xi MATRIX  
  
Sharon Hillier, PhD  
MATRIX Executive Director  and Clinical Trials Hub Co -lead 
Magee- Women’s Research Institute and Foundation (MWRIF)  
[ADDRESS_846572], Room B511  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003] 
Phone: 1 -[PHONE_4941] 
Fax: [PHONE_13200] 
Email: h [EMAIL_12093]  
 
Thesla Palanee -Phillips, PhD, MSc  
MATRIX Deputy Director  
Wits Reproductive Health and HIV Institute (Wits RHI)  
Hillbrow Health Precinct  
[ADDRESS_846573]  
Johannesburg, 2001 South Africa  
Phone: 27 -11-358-5471 
Fax: 27 -[PHONE_13201] 
Email: t [EMAIL_12094]  
 
Nyaradzo M. Mgodi, MBChB, M Med  
MATRIX Clinical Trials Hub Co -lead 
Harare Health and Research Consortium (HHRC)  
[ADDRESS_846574], Avondale  
Harare, Zimbabwe  
Phone: 263- 24-2704920  
Fax:  263 -24-2 704897  
Email: nmgodi@uz -ctrc.org  
 
Leila E. Mansoor, B.Pharm, PhD  
MATRIX Design to Delivery (D2D) Pi[INVESTIGATOR_5778] 2 Co -le ad 
Centre for the AIDS Programme  of Research in South Africa (CAPRISA)  
University of KwaZulu- Natal, 2nd Floor, Doris Duke Medical Research Institute  
[ADDRESS_846575]  
Durban, KwaZulu -Natal, 4001 South Africa  
Phone: 27 -(0)31- 655-0517 
Email: [EMAIL_12095] 
 A
lexandra Minnis, PhD  
MATRIX D2D Pi[INVESTIGATOR_5778] [ADDRESS_846576]  
Berkeley, CA [ZIP_CODE] [LOCATION_003]  
Phone: 1 -[PHONE_13202] 
Email: [EMAIL_12086] 
 
 
 
MATRIX -002, Version 1.[ADDRESS_846577]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
Phone: 412- 641-1403 
Email: [EMAIL_4600]  
 
Leslie Meyn, PhD  
B
iostatistician/Epi[INVESTIGATOR_633948] 
[ADDRESS_846578]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
Phone: 4 12-641-4233 
Fax: [PHONE_4942] 
Email: [EMAIL_4601]  
 
Tracy Zamborsky 
Data Manager  
MWRIF 
[ADDRESS_846579] nue 
Pi[INVESTIGATOR_9109], Pennsylvania [ZIP_CODE] [LOCATION_003] 
Email: [EMAIL_12096]  
 E
dward Livant, BSMT (ASCP), MPH  
MATRIX  Laboratory Quality Assurance/Quality Control (QA/QC) Coordinator 
MWRIF  
[ADDRESS_846580] , Room A536  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003] 
Phone: 412- 641-3772 
Fax: 412 -641-5290 
Email: [EMAIL_12097]  
 
May Beamer, BS  Laboratory Manager/Supervisor  MWRIF   
[ADDRESS_846581]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412- 641-6042  
Fax: 412 -641-6170  
Email: [EMAIL_12098]  
 
 
 
 
 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 xiii Ingrid Macio, PA-C 
MATRIX Clinical Research Manager (CRM)  
MW RIF   
[ADDRESS_846582]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003] 
Phone: [PHONE_13203] 
Fax: [PHONE_13204]  
Email: m [EMAIL_12099]  
 
Sharon Riddler, MD, MPH  
Independent Safety Physician (ISP)  
Division of Infectious Diseases  
Un
iversity  of Pi[INVESTIGATOR_633949], Suite [ADDRESS_846583]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003] Phone: 412- 383-1741 or 412 -383-1675 
Fax: 412 -383-2900 
Email: [EMAIL_1317]  
   
 
 
MATRIX -002, Version 1.0          24 May 2023 xiv [LOCATION_003]ID  
  
Shannon Allen, PhD  
MATRIX Agreement Officer Representative (AOR)  
Bureau of Global Health, Office of HIV AIDS, Research Division, [LOCATION_003]ID  
[ADDRESS_846584]  
Washington, DC [ZIP_CODE]  [LOCATION_003] 
Phone: [PHONE_13205] 
Email: s [EMAIL_12100] 
 
Mary Latka , PhD, MPH  
Chief, Microbicide s Branch  
Bureau of Global Health, Office of HIV AIDS, Research Division, [LOCATION_003]ID  
[ADDRESS_846585]  
Washington, DC [ZIP_CODE]  [LOCATION_003] 
Ema
il: mlatka@usa id.gov  
 
Kristin Vahle, MPH  
Project Program Analyst  
Bureau of Global Health, Office of HIV AIDS, Research Division, [LOCATION_003]ID  
[ADDRESS_846586]  
Washington, DC [ZIP_CODE]  [LOCATION_003] 
Email: [EMAIL_12101]  
 
 
 
  
 
 
MATRIX -002, Version 1.0          24 May 2023 xv Pi[INVESTIGATOR_32887] / MWRIF 
 
 
Lisa C. Rohan, PhD  
VALUE (Vaginal film as A Low -cost, User -administered, and Extended- release 
product) Project Principal Investigator  (PI) 
Department of Pharmaceutical Sciences  
U
niversity of Pi[INVESTIGATOR_633950]- Womens Research Institute  
[ADDRESS_846587]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003] 
Phone: [PHONE_13206] 
Fax: [PHONE_13200] 
Email: [EMAIL_5477]  
 
Sravan K. Patel, PhD  
VALUE Project Co -PI 
[INVESTIGATOR_633951]  
U
niversity of Pi[INVESTIGATOR_633950]- Womens Research Institute  
[ADDRESS_846588]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003] 
Phone: [PHONE_13207] 
Fax: [PHONE_13200] 
Email: [EMAIL_12102]  
  
  
 
 
MATRIX -002, Version 1.0          24 May 2023 xvi MATRIX -002 
 
Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal 
Films  
INVESTIGATOR SIGNATURE [CONTACT_625149] 1.0; 24 May 2023  
 
MATRIX: A [LOCATION_003]ID Project to Advance the Research and Development of Innovative 
HIV Prevention Products for Women 
 
Funded by:  
[CONTACT_633982] ([LOCATION_003]ID)  
 
A Non-IND S tudy  
 
I, the Investigator of Record, agree to conduct this study in full accordance with the provisions 
of this protocol  and all applicable protocol -related documents. I agree to conduct this study in 
compliance with [LOCATION_002] (US) Health and Human Service regulations (45 CFR 46); [LOCATION_003]ID 
regulations (2 CFR 200 and 22 CFR 225) ; standards of the International Conference for 
Harmonization Guideline for Good Clinical Practice ( ICH E6); Institutional Review 
Board/ Independent Ethics Committee (IRB/IEC) determinations; all applicable in -country, state, 
and local laws and regulations; and other applicable requirements (e.g., [LOCATION_003]ID ) and institutional 
policies.  
 
I agree to maintain all study records in accordance with protocol -specified protections of 
participants’ confidentiality and with site IRB/IEC policies and procedures. Study records must be 
maintained on -site for the entire implementation period of the study and a minimum of at least 
three years after completion of research . Pi[INVESTIGATOR_32887]/MWRIF  will inform the investigator/institution as to 
when these documents no longer need to be retained . 
 
I have read and understand the information in this protocol,  including the potential risks and side 
effects of the products under investigation,  and will ensure that all associates, colleagues, and 
employees assisting in the conduct of the study are informed about the obligations incurred by [CONTACT_100388].  
 
 
 ___________________________________
 
Name [CONTACT_262338]  (print) 
 
 
_________________________________     _____________________________ 
Signature [CONTACT_634078] -002, Version 1.0          24 May 2023 xvii MATRIX -002 
 
Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal 
Films  
PROTOCOL SUMMARY 
 
Short Title:   VALUE Placebo Film Study   
 Pharmaceutical  
Collaborator : Pi[INVESTIGATOR_32887]/MWRIF 
 
Funde rs:  [LOCATION_003]ID  
 
Protocol C o-Chair:  Nyaradzo M. Mgodi, MBChB, M Med 
 Protocol Co- Chair:   Alexandra Minnis, PhD  
 
Sample Size:   MATRIX -002 will enroll approximately 100 evaluable participants . MATRIX - 
   002 will also enroll a subset of up to 30 sexual partners of evaluable  
   participants for in-depth interview s (IDI) . 
 Study Population:  HIV seronegative adult (18 -45 years old) persons assigned female sex at  
   b irth who are at low risk of acquiring HIV infection  (henceforth referred to  
   as “participants”) , and sexual partners of evaluable participants   
   (henceforth referred to as “sexual partners”) . 
 
Study Sites:   Five sites in the U S and sub -Saharan Africa (SSA): 
   University of Pi[INVESTIGATOR_9109] (Pi[INVESTIGATOR_32887])/Magee-Womens Research Institute and  
   Foundation (MWRIF) clinical research site ( CRS); 
   Aurum Institute CRS;  
   Harare Health and Research Consortium (HHRC) CRS; 
   Wits Reproductive Health and HIV Institute (Wits RHI) CRS; and  
   Kenya Medical Research Institute (KEMRI) CRS . 
 Study Design:  Two-arm, randomized, multi -center trial  of monthly vaginal administration 
of two placebo prototype films. 
 Study Duration:  Approximately nine weeks  of follow -up per participant is planned with a 
projected accrual perio d of approximately 3-6 months. The total duration of 
the study will be approximately 6-9 months. 
 Study Products:  Placebo vaginal films A and B, 2” x 2” in size, which differ by [CONTACT_7823]. 
    
Study  Regimen:  Participants will be randomized (1:1) to insert  either placebo vaginal film A 
or placebo vaginal film B once monthly for two months . 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 xviii Figure 1: Study Visit Schedule  
  
 
 
 
 Primary Objective:  
 
 Acceptability  
• To assess the acceptability of two placebo film types (A and B) when administered vaginally 
once monthly for two months.  
 
Primary Endpoint:  
 
Acceptability  
• Participant rating s of overall satisfaction with us e of the placebo vaginal films.  
 Secondary Objectives: 
 
Safety  
• To assess the safety of two placebo film types (A and B) when administered vaginally once 
monthly for two months.  
 
Usability  
• To assess participants’ ability to properly insert the placebo vaginal film. 
 Secondary Endpoints:  
 
Safety  
• Proportion of participants with genitourinary Grade [ADDRESS_846589] . 
 
Usability  
• Proportion of participants with clinically assessed proper insertion (more than half of the vaginal film proximal to introitus). 
 Scr
V1Enr 
V224-[ADDRESS_846590] use  
 ≤[ADDRESS_846591] Film 
Note: phone  check  visits may be converted to other remote contact [INVESTIGATOR_12183] (e.g., SMS ) or in-person as needed and preferred by [CONTACT_633983] -002, Version 1.0          24 May 2023 xix Exploratory Objectives: 
 
Participant acceptability, attitudes and experiences  
• To explore  multiple dimensions of acceptability of two placebo film types (A and B) and  
participants’ attitudes towards and experiences with the vaginal film . 
 
Sexual partner attitudes and experiences  
• To explore sexual partner s’ attitudes towards and experiences with the vaginal film . 
 
Vaginal microenvironment 
• To assess the impact of placebo film use on  participants’ vaginal microenvironment when 
administered vaginally once monthly for two months.  
 
Social harms  and social benefits  
• To describe the reported experiences of social harms and social benefits over the course 
of vaginal film  use. 
 
Exploratory Endpoints:  
 
Participant acceptability, attitudes and experiences  
• Participant responses to quantitative acceptability assessments and IDI  questions . Multiple 
dimensions will be ex plored , including: 
o Vaginal film attributes, including acceptability (e.g., ease of insertion, burden, 
perceived effectiveness of film as delivery form) and preferences  
o Experience and comfort with  inserted vaginal film (e.g., expulsions, leakage, 
awareness of film during daily activities)  
o Experience during sex and menses  
o Vaginal practices  and concomitant vaginal product use while using vaginal film  
o Perception of sexual partners ’ attitudes towards vaginal film  
o Perceived  benefits and concerns/challenges  with the vaginal film as a future HIV 
prevention option  
o Interest in using vaginal film as a future HIV prevention option  
 
Sexual partner attitudes and experiences  
• Sexual partner responses during IDI related to:  
o Vaginal film attributes, including acceptability and preferences  
o Perception of participant’s experience using the vaginal film during the study  
o Physical sensation of the participant’s vaginal film use during sex (as relevant)  
o Perceived benefits and concerns/challenges with the vaginal film as a future HIV 
prevention option  
 
Vaginal microenvironment 
• Change from baseline in vaginal pH following film use during the two study phase s (i.e., 
with and without sexual abstinence  requirement) . 
• Change from baseline in quantity of selected vaginal microbiota following film use during 
the two study phases (i.e., with and without sexual abstinen ce requirement) . 
• Change from baseline in Nugent score following film use during the two study phases (i.e., 
with and without sexual abstinence requirement).  
 
 
MATRIX -002, Version 1.0          24 May 2023 xx  
Social harms  and social benefits  
• Participant self- report of social harms (i.e., non-clinical adverse  consequences of study 
participation or product use that may manifest in social, psychological or physical ways ). 
• Participant or sexual partner self- report of social benefits (e.g., positive consequences of 
product use disclosure, self- confidence, improved communication with intimate partner) 
resulting from vaginal film use and/or study participation . 
  
 
 
MATRIX -002, Version 1.0          24 May 2023 1 1 KEY ROLES  
 1.1 Protocol Identification  
 
Protocol Title:   Trial to Assess Acceptability and Safety of Two Placebo Prototype  
Vaginal Films 
 Protocol Number:   MATRIX -002 
 
Short Title:   VALUE Placebo Film Study  
 
Date:    24 May 2023 
 1.2 Funding Agenc y and Monitor Identification 
 
Funding Agenc y: [LOCATION_003]ID  
Bureau of Global Health, Office of HIV/AIDS, Research Division  
[ADDRESS_846592]  
Washington, DC [ZIP_CODE]  [LOCATION_003] 
  
Pharmaceutical Collaborator:  P itt/MWRIF 
 [ADDRESS_846593]  
 Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003] 
 Monitor  – African sites : African Clinical Research Organis ation (ACRO)  
 Phase 3, Second Floor Offices, Centurion Science Park,  
 [ADDRESS_846594], Lyttelton Manor, Centurion, 0157  
 South Africa  
  
Monitor – US site:  University of Pi[INVESTIGATOR_633952] (ECS- HSR) 
 Office of Research Protections  
 Heiber Building, Suite [ADDRESS_846595],  
 Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  [LOCATION_003] 
 
1.3 Laboratory(ie s) 
 
    MATRIX/MWRIF  
[ADDRESS_846596] nue 
Pi[INVESTIGATOR_9109], Pennsylvania [ZIP_CODE] [LOCATION_003] 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 2 1.4 Data Management 
 
Quantitative Data Center:  MATRIX/MWRIF  
[ADDRESS_846597] nue 
Pi[INVESTIGATOR_9109], Pennsylvania [ZIP_CODE] [LOCATION_003] 
 Q
ualitative Data Center:  RTI International  
   [ADDRESS_846598]  
   Berkeley, CA [ZIP_CODE]  [LOCATION_003] 
 
1.5 Clinical Research Management  
 
    MATRIX/MWRIF  
[ADDRESS_846599] substantially reduce the risk of 
sexual acquisition and transmission of HIV when applied to the genital or rectal mucosa. Vaginal 
films are an attractive dosing option for topi[INVESTIGATOR_2855] (vaginal) delivery of anti -HIV drugs. In terms of 
costs of production and manufacturing, films are relatively inexpensive, scalable, physically and 
chemically stable, and amenable to a range of active ingredients including combinations  of 
excipi[INVESTIGATOR_840] . In terms of use, films are discreet, portable, and easy to store. Vaginal films can 
deliver fixed doses of pharmacologically active agents with minimal mess or leakage and without 
an applicator. Due to their small volume, films also generate no significant alterations in innate microbiome as shown in previous clinical evaluation  for our FAME program (U19 AI082639
1, U19 
AI1202492), and incur less dilution of endogenous antiviral or antibacterial properties in vaginal 
fluids as compared to vaginal gels. Feedback from women in several clinical and focus -group 
studies – [STUDY_ID_REMOVED] (FACE)3, [STUDY_ID_REMOVED] (FLAG)4, [STUDY_ID_REMOVED] (Quatro)5, PASII6, 
[STUDY_ID_REMOVED] (MIST)7,8, [STUDY_ID_REMOVED] (FAME 02)9, FAME 02B10, [STUDY_ID_REMOVED] (VAST)11, 
[STUDY_ID_REMOVED] (FAME 04)12, [STUDY_ID_REMOVED] (FAME 05)13, [STUDY_ID_REMOVED] (FAME 101)14, FAME 102  
(unpublished data), [STUDY_ID_REMOVED] (FAME 103)15, [STUDY_ID_REMOVED] (FAME 103B)16 – supported the 
willingness for women to us e such products and the advancement and development of vaginal 
films for discrete HIV prevention.5,6,9-11 
 The long- term goal of the VALUE (Vaginal film as A Low- cost, User -administered, and Extended -
release product ) project is to develop and evaluate an extended -release vaginal film containing 
dapi[INVESTIGATOR_12979], a potent NNRTI, which could provide protection from HIV for at least one month 
following a single application. Previously, the Pi[INVESTIGATOR_32887]/MWRIF  team developed and evaluated quick 
dissolve films for on -demand vaginal administration of several anti- HIV drug candidates including 
dapi[INVESTIGATOR_12979].
9,10,12,[ADDRESS_846600] also confirmed the feasibility of design of a monthly film platform 
(LATCH R61/33 AI142687)17 in a nonhuman primate (macaque) model. Furthe rmore, retention 
of films within the vagina was established during menses and sex in the macaque model. The 
VALUE project aims to design a one- month vaginal film containing dapi[INVESTIGATOR_633953] (API) to provide a low cost and convenient option for women for 
protection from HIV infection  through sex . Previous studies  have  supported the acceptability and 
safety of the  quick dissolve and 7 -day sustained relea se films , but there is limited data regarding  
a monthly vaginal film . 
   
MATRIX -002 is a randomized trial assessing the acceptability and safety of two vaginal placebo 
film products that differ in shape . Specifically, the 2"x2" films differ with respect to shape of the 
corners. One film product is square in shape, while the second product has rounded edges on all 
four corner s. These differences may impact  product acceptability and usability. The proposed 
study will evaluate the acceptability , safety,  and self-insertion success of these [ADDRESS_846601] potential to benefit from acc ess to a range of HIV 
prevention products.  This study of the one-month placebo vaginal film will examine overall 
 
 
MATRIX -002, Version 1.0          24 May 2023 4 satisfaction with the film after using it, multiple components  and correlates of acceptability, as 
well as topi[INVESTIGATOR_633954]. The design of these assessments is informed 
by a recent systematic review of the Theoretical Framework of Acceptability (Sekhon),18 published 
by [CONTACT_633984].19 
 
Additionally, by [CONTACT_633985] -002 participants used the vaginal film, this study hopes to gain a deeper understanding 
of how partners’ opposition or support may affect a user’s ability to safely, correctly and 
consistently use a vaginal film for HIV preventio n in the future. This, in turn, can contribute to 
efforts to mitigate concerns and cultivate support among men for HIV prevention research, HIV 
prevention products, and microbicide use.  Data from in-depth interviews ( IDI) may also provide 
insight to the strategies and counseling messages that could be used in couples’ education and counseling for future trials, with the objective of promoting use of the vaginal film.  
 
2.2 Description of Placebo Prototype Vaginal Films  
 
2.2.1  Placebo Vaginal Film A  
 
Placebo Vaginal Film A is made of film- forming polymers , release -modifying polymers, and 
plasticizers . It differs from Placebo Vaginal Film B by [CONTACT_633986] (square vs. rounded edge s). All 
the excipi[INVESTIGATOR_633955] a history of pharmaceutical use  
(https://www .accessdata.fda.gov/scripts/cder/iig/index.cfm ). The formulations contain multiple 
excipi[INVESTIGATOR_840], namely, hydroxypropyl cellulose, Hypromellose, hydroxyethyl cellulose, a mmonio 
methacrylate copolymer type B , propylene glycol, and polyethylene glycol. A vaginal film 
containing similar excipi[INVESTIGATOR_633956] 101 study ( Study Registry ID: [REMOVED])
14 without any adverse outcomes in healthy participants . 
 
2.2.2  Placebo Vaginal Film B  
 
Placebo Vaginal Film B is also made of film-forming polymers , release -modifying polymers, and 
plasticizers . It differs from Placebo Vaginal Film A by [CONTACT_633986] (square vs. rounded edges) . 
 
2.[ADDRESS_846602] obtained data 
comparing films with other dosage forms, explored end -user acceptability in the context of sexual 
intercourse and obtained information from end -users that has directed our target critical quality 
attributes (CQAs) including size, color and texture. We also gained insights that informed film use 
instructions and explored the relationship between formulation modification, end -user 
acceptability, and ease of use experiences with the product. Overall, women have found the vaginal film platform to be acceptable and easy to use.  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 5 2.4 Rationale for Study Design  
 The primary objective of this study is to assess the acceptability of two placebo film types (A and 
B) when administered vaginally once monthly for two consecutive months. Previous research has 
supported the safety of the film excipi[INVESTIGATOR_840], but there is  little data on the acceptability of a monthly 
vaginal film. The study is designed to assess acceptability parameters in the first month in ideal 
conditions (i.e., pelvic rest). During this phase, we anticipate that participants will be unaware of the film ’s presence in the vagina  based on prior clinical research with vaginal film products; 
however, it is possible that with time the film might contribute to discharge as it dissolves and/or 
be expelled during menses. The first month, during which participants are instructed to refrain 
from putting anything into  the vagina, will provide valuable insight into user experiences with the 
film without extraneous interruptions. The second month, during which participants are allowed to have sexual intercourse and use vaginal products , will provide important information  about 
user experience with the film with vaginal stimuli. We anticipate that the film will stay in place 
despi[INVESTIGATOR_633957]. By [CONTACT_633987] (e.g., 
acceptability and insertion success) and what attributes potentially contribute to these outcomes. Aspects of the film that lead to better performance will be incorporated into future film design . 
 
This study has been designed to add to our knowledge about potential end-users’ acceptability 
of and perceptions towards long- term (1 month) use of films with different shapes . Acceptability 
will be assessed through quantitative questionnaires and IDIs with users and, among a subset, 
IDIs with their sexual partners. Instructional materials will be utilized to familiarize users with the 
insertion process. These materials were designed based on participant feedback from previous 
trials. Product misplacement such as partial insertion has been noted in clinical trials of vaginal 
films previously conducted at the University of Pi[INVESTIGATOR_9109].
[ADDRESS_846603] found the vaginal film to be safe and acceptable as quick dissolve and 7 -day sustained release 
formulations, but  the 1-month long vaginal film has never been tested in women. This placebo 
study will provide critical information on acceptability,  safety,  usability, and user experience, 
which will be incorpo rated in the dapi[INVESTIGATOR_633958].  
Finally, although [STUDY_ID_REMOVED] (MTN- 032) and other studies have shown that male partners play 
an important role in women’s adherence to microbicides,
20 more research is needed to understand 
how this manifests specifically in the context of women’s use of extended- release vaginal films. 
Therefore, perceptions of the vaginal film will also be elicited from sexual partners of study 
participants.  
 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 6 3 OBJECTIVES  
 3.1 Primary Objective  
 
 Acceptability  
• To assess the acceptability of two placebo film types (A and B) when administered 
vaginally once monthly for two months.  
 3.2 Secondary Objectives 
 
Safety  
• To assess the safety of two placebo film types (A and B) when administered vaginally 
once monthly for two months.  
 
Usability  
• To assess participants’ ability to properly insert the placebo  vaginal film. 
 3.3 Exploratory Objectives  
 
Participant acceptability, attitudes and experiences  
• To ex plore multiple dimensions of acceptability of two placebo film types (A and B) and  
participants’ attitudes towards and experiences with the vaginal film . 
 
Sexual partner attitudes and experiences  
• To explore sexual partners’ attitudes towards and experiences with the vaginal film . 
 
Vaginal microenvironment 
• To assess the impact of placebo film use on  participants’  vaginal microenvironment when 
administered vaginally once monthly for two months.  
 
Social harms  and social benefits  
• To describe the reported experiences of social harms and social benefits over the course 
of vaginal film  use. 
 
 
4 STUDY DESIGN  
 
4.1 Identification of Study Design  
 MATRIX -002 is a t wo-arm, randomized, multi -center trial to assess acceptability, safety and 
usability  of two placebo prototype films when administered vaginally once monthly for two 
months.  
 
 
MATRIX -002, Version 1.0          24 May 2023 7 4.2 Summary of Major Endpoints  
 Primary Endpoints: 
 
Acceptability  
• Participant ratings of overall satisfaction with using the placebo vaginal films . 
 
Secondary Endpoints:  
 
Safety  
• Proportion of participants with genitourinary Grade [ADDRESS_846604] . 
 
Usability  
• Proportion of participants with clinically assessed proper insertion (more than half of the 
vaginal film proximal to introitus). 
 Explorato ry Endpoints:  
 
Participant acceptability, attitudes and experiences  
• Participant responses to quantitative acceptability assessments and IDI questions. Multiple dimensions will be e xplored, including: 
o Vaginal film attributes, including acceptability ( e.g., ease of insertion, burden, 
perceived effectiveness of film as delivery form) and preferences  
o Experience and comfort with inserted vaginal film (e.g., expulsions, leakage, 
awareness of film during daily activities)  
o Experience during sex and menses  
o Vaginal practices  and concomitant vaginal product use while using vaginal film  
o Perception of sexual partners ’ attitudes towards vaginal film  
o Perceived benefits and concerns/challenges with the vaginal film as a future HIV prevention option  
o Interest in using vaginal film as  a future HIV prevention option  
 
Sexual partner attitudes and experiences  
• Sexual partner responses during IDI related to:  
o Vaginal film attributes, including acceptability and preferences  
o Perception of participant’s experience using the vaginal film during the study  
o Physical sensation of the participant’s vaginal film use during sex (as relevant)  
o Perceived benefits and concerns/challenges with the vaginal film as a future HIV 
prevention option  
 
Vaginal microenviron ment 
• Change from baseline in vaginal pH following film use during the two study phases (i.e., with and without sexual abstinence  requirement).  
• Change from baseline in quantity of selected vaginal microbiota following film use during the two study phases (i.e., with and without sexual abstinen ce requirement).  
• Change from baseline in Nugent score following film use during the two study phases (i.e., with and without sexual abstinence requirement).  
 
 
MATRIX -002, Version 1.0          24 May 2023 8  
Social harms  and social benefits  
• Participant self- report of social harms ( i.e., non- clinical adverse  consequences of study 
participation or product use that may manifest in social, psychological  or physical ways ).  
• Participant and sexual partner self -report of social benefits (e.g., positive consequences 
of product use disclosure, self -confidence, improved communication with intimate partner) 
resulting from vaginal film use and/or study participation . 
 4.[ADDRESS_846605] of HIV seronegative adult (18 -45 years old) persons assigned 
female sex at birth who meet the criteria outlined in Sections 5.2.1  and 5.3, and sexual partners 
who meet eligibility criteria as described in Section 5.2.2. 
 4.4 Time to Complete Accrual  
 The time to complete accrual at all sites is anticipated to be approximately 3-6 months.  
 
4.5 Study Groups  
 
MATRIX -002 will enroll approximately 100 evaluable participants , randomized (1:1) to either 
placebo vaginal film A or B .
 MATRIX -002 will also enroll a subset of up to 30 sexual partners for 
an IDI. See Section 10.3  for more details.  
 4.6 Expected Duration of Participation  
 Once randomized to placebo film A or B, participants will complete a pproximately nine weeks of 
follow -up. The total duration of the study will be approximately 6-9 months . 
 
4.7 Sites  
 
The following f ive sites in the [LOCATION_002] and sub- Saharan Africa ( SSA) will take part in 
MATRIX -002: University of Pi[INVESTIGATOR_9109] (Pi[INVESTIGATOR_32887])/Magee -Womens  Research Institute and Foundation 
(MWRIF) clinical research site (CRS), Aurum Institute CRS , Harare Health and Research 
Consortium (HHRC) CRS , Wits Reproductive Health and HIV Institute (Wits RHI) CRS , and Kenya 
Medical Research Institute (KEMRI) CRS.  
  
[ADDRESS_846606]  will be selected for participation in an IDI. 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 9 5.1.1  Recruitment  
 Participants will be recruited from a variety of sources  across sites including, but not limited to, 
existing databases (as permitted by [CONTACT_633988] [PHI]), 
primary care health clinics, family planning clinics, HIV testing facilities, gynecology clinics, 
institutions of higher learning, other community -based organizations , and through community 
outreach activities . Recruitment materials will be approved by [CONTACT_633989] /Independent Ethics Committees  (IRB/IEC ) prior to use  per local requirements .
 Community 
education strat egies, including group sessions, may be employed as part of participant/partner 
outreach.  Sites will develop and implemen t local standard operating procedures (SOP) to target 
potential participants for recruitment.  5.1.2  Retention 
 Once a participant is enrolled in MATRIX- 002, study sites will make every effort to retain the 
participant in follow -up to minimize possible bias associated with loss -to-follow -up (LTFU) . An 
average retention rate of 95% will be targeted across sites. Site s will develop and implement local 
SOPs to target and ensure high rates of retention.  
 5.[ADDRESS_846607] meet all the following criteria prior to Enrollment  (unless otherwise 
specified):  
 
1) Aged 18 to 45 years (inclusive)  at Screening, verified per site SOP . 
 
2) Assigned female sex at birth.  
 
3) Able and willing to provide written informed consent to be screened for and enrolled in 
MATRIX -002 in one of the study languages (as specified in site SOP) . 
 
4) Able and willing to provide adequate contact/ locator information, as defined in site SOP.  
 
5) Able and w illing to comply with all protocol requirements, including : 
• Abstaining from all receptive sexual intercourse  (vaginal, anal, digital, oral) for the first 
month of product use.  
• Abstaining from using other intravaginal products for the first month of product use. 
• Abstaining from engaging in intravaginal practices for the first month of product use.  
• Refraining from participation in other research studies for the duration of the study
 
unless approved by [CONTACT_633990] (PSRT) . 
• Responding to scheduled phone /short message service (SMS) contacts.  
• Attending all clinic follow -up visits.  
 
6) HIV-uninfected based on testing performed at Screening and Enrollment (per protocol 
algorithms in Appendix II). 
 
7) Per participant report, if in a relationship, must be in a mutually monogamous relationship 
with a partner who is not known to be HIV  positive or  to currently  have a sexually transmitted 
infection (STI ). 
 
 
MATRIX -002, Version 1.0          24 May 2023 10  
8) Negative urine pregnancy test at Screening and Enrollment . 
 
9) Participants over the age of 21 (inclusive) must have documentation of a Grade [ADDRESS_846608] 3 years  prior to Enrollment , or a Grade 1 Pap smear at Screening with no 
treatment required , per the Female Genital Grading Table for Use in Microbicide Studies 
Addendum 1 (Dated November 2007) to the DAIDS Table for Grading Adult and Pediatric 
Adverse Events, Corrected Version 2.1, July 2017. 
 
10) Protected from pregnancy starting two weeks before Screening and continuing for the 
duration of study participation by [CONTACT_633991] ; 
effective methods include: 
• Hormonal methods  except vaginal rings 
• Copper intrauterine device ( IUD) 
• Sterilization of participant 
• Correct and consistent condom use (for US site only)  
• Abstinence from penile- vaginal intercourse  
 
5.2.[ADDRESS_846609] meet all of the following criteria to 
be eligible for inclusion in the study:  
1. Identifies as a sexual partner of a MATRIX -[ADDRESS_846610] (as specified in site SOP) . 
3. Able and willing to provide written informed consent in one of the study languages  (as 
specified in site SOP) . 
4. Able and willing to complete the required study procedures.  
5. Must be [ADDRESS_846611] not meet a ny of  the following criteria prior to Enrollment (unless 
otherwise specified):   
 
1) Per participant report at Screening and Enrollment, intends to do any of the following during 
the study participation period:  
• Become pregnant.  
• Breastfeed.  
• Relocate away from the study site.  
• Travel away from the study site for a time period that would interfere with product 
resupply and /or study participation.  
 
2) Positive HIV test a t Screening or Enrollment.  
 
3) Positive test for  
Trichomonas vaginalis  (TV), Neisseria gonorrhea (GC), Chlamydia tracho matis  
(CT), or Treponema pallidum  (Syphilis ) at Screening or  (per participant report) treated for 
potential STI  within past 12 months . 
 
4) Diagnosed with urinary tract infection ( UTI), pelvic inflammatory disease ( PID), or 
reproductive tract infection (RTI) requiring treatment per WHO guidelines at Enrollment . 
 
 
MATRIX -002, Version 1.0          24 May 2023 11  
Note: Otherwise eligible participants diagnosed during screening with a UTI, symptomatic 
yeast infection or symptomatic BV infection are offered treatment consistent with WHO 
recommenda tions. If treatment is completed and symptoms have resolved within 45 days of 
obtaining informed consent for screening, the participant may be enrolled.  
 
5) Clinically apparent Grade 2 or higher pelvic exam finding  per the DAIDS Table for Grading 
Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017 and/or Addenda 1 
(Female Genital  Grading Table for Use in Microbicide Studies  [Dated November 2007]) at 
Enrollment.  
Note: Otherwise  eligible participants with exclusionary pelvic exam findings at Screening may 
be enrolled/randomized if treatment is begun at least [ADDRESS_846612] improved to a non -exclusionary severity grading or resolved by [CONTACT_544213].  
Spotting/bleeding will be considered exclusionary only if greater  than what would be expected 
from contraceptive use . 
 
6) Participant report and/or clinical evidence of any of the following:  
• Known adverse reaction to any of the study product  mater ials (ever).  
• Hysterectomy . 
• Surgical procedure involving the pelvis in the 30 days prior to Enrollment . 
• Use of diaphragm, NuvaRing, or (for African sites only) spermicide for contraception  
in the two weeks prior to Screening. 
• Antibiotic or antifungal (oral or intravaginal) therapy within 7 days of Enrollment . 
• Prior use of post-exposure prophylaxis ( PEP) or oral pre-exposure prophylaxis (PrEP) 
(including F TC/TDF) in the 4 weeks prior to Screening or any prior use of long -acting 
systemic PrEP (including cabotegravir or islatravir). 
• Use of any of the following in the 12 months  prior to Screening: stimulants (cocaine 
[including crack], methamphetamine, or non- physician prescribed pharmaceutical-
grade stimulants), or inhaled nitrates, or illicit injection drug use of any kind . 
• At Screening or Enrollment, as determined by [CONTACT_30122] 
(IoR)/designee, has any significant uncontrolled active or chronic cardiovascular, 
renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respi[INVESTIGATOR_696], immunologic disorder or infectious disease.  
 
7) Has any of the following laboratory abnormalities at Screening:  
• Grade 2 or higher Aspartate aminotransferase (AST), alanine transaminase (ALT) , 
creatinine, or Hemoglobin  per the  DAIDS Table for Grading Adult and Pediatric Adverse 
Events, Corrected Version 2.1, July 2017 . 
 
8) Has any other condition that, in the opi[INVESTIGATOR_625078]/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.  
 
5.[ADDRESS_846613] not take part in observational or 
qualitative studies while taking part in MATRIX -002, unless approved by [CONTACT_111153] . Each site will 
be responsible for defining procedures for management and prevention of co- enrollment prior to 
initiation.  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 12 Should any participant report concurrent participation in contraindicated studies after enrolling in 
MATRIX -002, the IoR/designee will consult the PSRT regarding ongoing product use and other 
potential safety considerations a ssociated with co- enrollment , or regarding potential product 
acceptability considerations associated with co- enrollment . 
  
[ADDRESS_846614] s being used in this study are the placebo prototype vaginal films A and B .
 The two 
films differ by [CONTACT_633986] (square vs. rounded edges) . At each of the study sites, participants will 
be randomized (1:1) to receive either placebo  vaginal film A or B. Each participant will receive 
one dose per month for two consecutive months, for a total of 2 doses of placebo vaginal film. 
 Figure 2: Study Product Regimen 
 
  
 
  
 
 
6.2 Administration  
 
After eligibility is confirmed and the participant is randomized to one of two films ( Placebo Film A 
or B) site staff will retrieve the assigned film from the pharmacy. Participants will self-insert the 
film at the study clinic, and film placement will be checked visually by a study clinician. If less 
than half of the vaginal film is proximal to introitus, participants will have the film removed and 
asked to try again with a new film. If less than half of the vaginal film is proximal to introitus  a 
second time , participants will have the film removed and a third film inserted by [CONTACT_633992] a speculum . 
 
6.[ADDRESS_846615] Formulation and Storage    
 
Films are composed of film -forming polymers, release modifying polymers, and plasticizers. The 
2”x2” films will be packaged into foil -lined pouches and stored at room temperature. Good Scr
V1Enr 
V224-[ADDRESS_846616] use  
 ≤[ADDRESS_846617] Film 
Note: phone check visits may be converted to other remote contact [INVESTIGATOR_12183] (e.g., SMS ) or in-person as needed and preferred by [CONTACT_633983] -002, Version 1.0          24 May 2023 13 Manufacturing Practice (GMP ) stability testing will be conducted for the clinical trial product 
material as per ICH guidelines.  
 
6.[ADDRESS_846618] release testing includes GMP Microbial Limits Testing (USP61/62).  
After product release, the packaged study product will be provided to th e clinical sites.   
 
6.4.[ADDRESS_846619](s) will maintain complete accountability records of all stud y 
products received for this protocol and dispensed to participants.  Additional documentation will 
be required for study product returns, destruction (if applicable).  
 
6.4.[ADDRESS_846620] month of vaginal film use .  
 6.6 Concomitant Medications  
 
All concomitant medications will be recorded on case report forms ( CRF) for participants starting 
at Screening. Concomitant medications include any prescription, over the counter or 
herbal/traditional medication or preparation . Enrolled study participants may use concomitant 
medications during study participation but will be asked to abstain from  medications and products 
noted as prohibited  in Section 6.7. 
 
6.7 Prohibited Medications, Products and Practices 
 Participants will be instructed to practice “pelvic rest” during the first month of participation. This means nothing should enter the vagina: fingers, penis, tampon, toy s, etc.
 Participants will be 
asked to abstain from any penetrative sex (i.e., penile or with the use of an instrument that 
penetrates past the labia majora) , intravaginal practices (e.g., douching) , and use of all 
intravaginal medications and products during the first month of participation. If a participant 
reports receptive sexual activity, douching, or use of an intravaginal medication or product, the 
site staff will counsel the participant about  the importance of adhering to the protocol (if reported 
 
 
MATRIX -002, Version 1.[ADDRESS_846621] use) and record these behaviors  on the appropriate CRF. During 
the second month of participation there are no restrictions on sexual activity, intravaginal practices or products.  Please reference the MATRIX- 002 Study Specific Procedures (SSP) Manual 
for additional details.  
 
 
7 STUDY PROCEDURES  
 An overview of the study visits and evaluations schedule is provided in Appendix I. Presented in 
this section is additional information on visit -specific study procedures. Detailed instructions to 
guide and standardize procedures across sites as well as to specify the visit windows are provided in the MATRIX- 002 SSP Manual. 
 Figure 3: Study Visit Schedule  
  
 
 
 
 
 
7.1 Screening Visit   
 
Potential participants will provide written informed consent prior to any study procedures 
including all screening assessment s to determine  their eligibility to take part in the study. 
Participants will be counselled to abstain from sex and  from use of intravaginal products (see 
Section 6.7) for the fi rst month of study product use. Eligibility determination will include baseline 
demographics and medical history, physical  and pelvic  examination, urine pregnancy test (UPT), 
and HIV/STI screening.
 If eligible, potential participants will return within 45 days for their 
Enrollment Visit . For women with a regular menstrual cycle, the Enrollment Visit (and subsequent 
clinic visits if enrolled) will ideally be scheduled  when the potential participant is not on her p eriod.  
 
Note: Multiple visits may be conducted within the screening window to complete all required 
screening procedures , including any procedures that need to be repeated (e.g., blood draw), if 
necessary. 
 
Note: Potential participants who fail their first screening attempt may be re- screened on ce. 
 Scr
V1Enr 
V224-[ADDRESS_846622] use  
 ≤[ADDRESS_846623] Film 
Note: phone check visits may be converted to other remote contact [INVESTIGATOR_12183] (e.g., SMS ) or in-person as needed and preferred by [CONTACT_633993] -002, Version 1.0          24 May 2023 15 Table 1: Screening Visit  
Screening Visit  – Visit 1   
Component  Procedures  
Administrative and Regulatory • Obtain written informed consent  for screening and enrollment (sites 
may split screening and enrollment consent if requested/required by 
[CONTACT_1744]/IEC ) 
• Assign a unique Participant Identification (PTID) number  
• Assess eligibility  
• Collect demographic information  
• Collect locator information  
• Provide reimbursement  
• Schedule next visit/contact*  
Behavioral /Counseling  • HIV pre - and post -test counseling  
• HIV/STI risk reduction counseling  
• Protocol counseling  (including regarding pelvic rest  in Month 1)  
Clinical  • Collect medical and menstrual history  
• Collect concomitant medications  
• Perform full physical examination  
• Perform pelvic examination (including bimanual exam)  
• Treat or prescribe treatment for RTI/UTI/STIs*  
• Provide available test results  
Laboratory  Saliva  • HIV test(s) (only at sites with CLIA  certification ) 
Urine  • Urine pregnancy test  
• Urine dipstick/culture*  
Blood  • HIV test(s) (not required for sites that conduct  saliva testing)  
• Complete blood count (CBC)  
• Serum creatinine  
• AST/ALT 
• Syphilis serology  
Pelvic  • Nucleic acid amplification test (NAAT) for GC/CT /TV 
• Pap test^  
• Saline/potassium hydroxide (KOH) wet mount for candidiasis and/or 
bacterial vaginosis (BV)*  
*If indicated and/or per local standard of care ; ^ if indicated (if participant is unable to provide documentation of a 
normal  Pap test  within 3 years prior to enrollment)  
 
7.2 Enrollment Visit – Visit 2  (Day 0) 
 
Within [ADDRESS_846624] their eligibility 
confirmed  and be randomized (1:1) to placebo vaginal film A or B . Participants will again be 
counselled to abstain from sex and  from use of vaginal products (see Section 6.7) for the first 
month of study product use. Study staff will review instructional materials about the film and film 
insertion with participants prior to insertion of the first film. Participants will be asked to provide 
a urine sample for a UPT, undergo HIV/STI screening and a pelvic examination, pr ovide a blood 
sample for plasma archive, and complete an interviewer -administered  baseline acceptability 
questionnaire about the film. P articipants will then be asked to insert the film at the study clinic , 
and film placement will be checked visually by a study clinician.  If less than half of the vaginal 
film is proximal to introitus , participants will have the film removed and asked to try again  with a 
 
 
MATRIX -002, Version 1.[ADDRESS_846625] film inserted by [CONTACT_418025] a speculum . Participant 
attempts to insert the film will be documented on the appropriate CRF.  
 
Table 2: Enrollment Visit – Visit 2 (Day 0) 
Enrollment Visit  – Visit 2  (Day 0) 
Component  Procedures  
Administrative and Regulatory 
 • Review informed consent or (for sites that use separate screening and 
enrollment consent forms if requested/required by [CONTACT_1744]/IEC) obtain 
written informed consent for enrollment  
• Assess and confirm eligibility  
• Review/update locator information  
• Randomization  
• Provide reimbursement 
• Schedule next visit/contact*  
Behavioral /Counseling  • HIV pre - and post -test counseling  
• HIV/STI risk reduction counseling  
• Protocol counseling (including regarding pelvic rest  in month [ADDRESS_846626] use) 
• Review instructional materials  
• Baseline behavioral questionnaire (acceptability and risk/protective 
behaviors)  
• Post-insertion behavioral assessment  
Clinical  • Review/update medical and menstrual history  
• Review/update concomitant medications  
• Perform targeted physical examination * 
• Perform pelvic examination with speculum  
• AE assessment  
• Treat or prescribe treatment for RTI/UTI/STIs*  
• Visual examination by [CONTACT_633994]  
• Clinician  film insertion assessment  
• Provide available test results  
Laboratory  Saliva  • HIV test(s) (only at sites with CLIA  certification ) 
Urine  • Urine pregnancy test  
• Urine dipstick/culture*  
Blood  • HIV test(s) (not required for sites that conduct  saliva testing)  
• Plasma for archive  
• CBC*  
• Serum creatinine*  
• AST/ALT*  
Pelvic  • NAAT for GC/CT /TV 
• Saline/KOH wet mount for candidiasis and/or BV*  
• Vaginal Gram stain  
• Vaginal swab(s) for microbiota  
• Vaginal pH  
 
 
MATRIX -002, Version 1.0          24 May 2023 17 Enrollment Visit  – Visit 2  (Day 0) 
Component  Procedures  
Study Product /Suppl ies • Provide vaginal film for self -insertion at clinic  
• Clinician insertion of vaginal film at clinic ( only if participant fail s two 
attempt s) 
*If indicated and/or per local standard of care  
 
7.3 Follow -up Visits/ Contacts 
 7.3.1  Phone check- in ([ADDRESS_846627] insertion) – Visit [ADDRESS_846628] the study participant via telephone or short message service ( SMS) to assess experiences 
with the first vaginal film 
in situ. Participants who prefer to complete these procedures in -person 
may elect to do so. The staff member will ask the participant about initial experiences with the film in place, any concerns about product placement and leakage, and elicit any questions or 
other concerns. If conducted a s a phone conversation, this is anticipated to be less than 5 
minutes. If conducted as an SMS exchange, this is anticipated to be less than 5 text messages from each party. If participants raise any concerns that require more in -depth discussion, the 
staff member will assess the proper follow -up method.  
 
Table 3:  Phone check -in ([ADDRESS_846629] insertion) – Visit 3  
Phone check -in ([ADDRESS_846630] insertion) – Visit 3  
Component  Procedures  
Administrative and Regulatory  • Provide reimbursement  
Behavioral/Counseling  • Brief behavioral a ssessment (concerns and comfort with film use ) 
 7.3.2  1-week and 2 -week Telephone  Contacts – Visits 4 and 5 (7 and 1 4 days after 
Visit 2 ) 
 
Approximately o ne week and two weeks after Enrollment,  the study team will contact [CONTACT_633995], comfort with the film, and any 
concerns.  Participants who prefer to complete these procedures in- person may elect  to do so . 
Participants who report AEs or otherwise express concerns may be asked to come in for an Interim 
Visit, if willing, to conduct additional counseling and/or testing as needed.  
 Table 4: 1-week and 2 -week Telephone  Contacts – Visits 4 and 5 (7 and 1 4 days after 
Visit 2 ) 
1-week and 2 -week Telephone  Contacts – Visits 4 and 5 (7 and 1 4 days after Visit 2 ) 
Component  Procedures  
Administrative and Regulatory  • Review/update locator information  
• Provide reimbursement 
• Schedule next visit/contact  
[CONTACT_625111]/Counseling  • Brief behavioral assessment (concerns and comfort with film use) 
• Protocol counseling*  
 
 
MATRIX -002, Version 1.0          24 May 2023 18 1-week and 2 -week Telephone  Contacts – Visits 4 and 5 (7 and 1 4 days after Visit 2 ) 
Component  Procedures  
Clinical  • Review/update medical and menstrual history  
• Review/update concomitant medications  
• AE assessment 
• Provide available test results  
*If indicated and/or per local standard of care  
 7.3.3  4-week  Visit – Visit 6 (28 days after Visit 2 )   
 
At least four weeks after Enrollment, participants will come to the clinic for acceptability and safety evaluation for the first film, the clinician will remove any visible film, and the participant 
will insert a second film. Study staff will once again review instructional materials about t he film 
and film insertion with participants prior to insertion of the second film. The second film will be 
the same film shape the participant was randomized to at enrollment , and film placement will be 
checked visually by a study clinician . If less than half of the vaginal film is proximal to introitus, 
participants will have the film removed and asked to try again with a new film. If less than half 
of the vaginal film is proximal to introitus a second time , participants will have the film removed 
and a third film inserted by [CONTACT_19811] a speculum . Participant attempts to insert the film 
will be documented on the appropriate CRF. During the second month, there are no restrictions 
on vaginal product use or sex. Participants will be ask ed to provide a urine sample for  a UPT, 
undergo HIV/ STI testing and a pelvic examination, and complete  an interviewer -administered 
acceptability questionnaire about the film.  
 
Table 5: 4- week  Visit – Visit 6 (28  days after Visit 2 ) 
4-week  Visit  – Visit 6 (28 days after Visit 2 ) 
Component  Procedures  
Administrative and Regulatory 
 • Review/update locator information  
• Provide reimbursement  
• Schedule next visit/contact  
[CONTACT_625111] /Counseling  • HIV pre - and post -test counseling  
• HIV/STI risk reduction counseling  
• Protocol counseling (including regarding sexual partner IDI 
component  and product use) 
• Review instructional materials  
• Follow -up b ehavioral questionnaire (acceptability and product use 
experiences ; intravaginal practices and sexual activity ) 
• Post-insertion  acceptability  assessment  
Clinical  • Review/update medical and menstrual history  
• Review/update concomitant medications  
• Perform targeted physical examination * 
• Perform pelvic examination with speculum  
• AE assessment  
• Treat or prescribe treatment for RTI/UTI/STIs*  
• Visual examination by [CONTACT_633994]  
• Clinician film  insertion assessment  
• Provide available test results  
 
 
MATRIX -002, Version 1.0          24 May 2023 19 4-week  Visit  – Visit 6 (28 days after Visit 2 ) 
Component  Procedures  
Laboratory  Saliva  • HIV test(s) (only at sites with CLIA  certification ) 
Urine  • Urine pregnancy test  
• Urine dipstick/culture*  
Blood  • HIV test(s) (not required for sites that conduct  saliva testing)  
• CBC*  
• Serum creatinine*  
• AST/ALT*  
Pelvic  • NAAT for GC/CT /TV 
• Saline/KOH wet mount for candidiasis and/or BV*  
• Vaginal Gram stain  
• Vaginal swab(s) for microbiota  
• Vaginal pH  
Study Product /Suppl ies • Provide vaginal film for self -insertion at clinic  
• Clinician insertion of vaginal film at clinic ( only if participant fail s two 
attempt s) 
• Offer male condoms  
*If indicated and/or per local standard of care  
 
7.3.4  Phone check- in (24 -72 hours after 2nd insertion) – Visit [ADDRESS_846631], any experiences 
of leakage, and any other concerns. If conducted as a phone conversation, this is anticipated to 
be less than 5 minutes. If conducted as an SMS exchange, this is anticipated to be less than 5 
text messages from each party. If participants raise any concerns that require more in -depth 
discussion, the staff member will assess the proper follow -up method . 
 
Table 6:  Phone check- in (24 -72 hours after 2nd insertion) – Visit 7 
Phone check -in (24 -72 hours after 2nd insertion) – Visit 7 
Component  Procedures  
Administrative and Regulatory • Provide reimbursement  
Behavioral/Counseling  • Brief behavioral a ssessment (concerns and comfort with film use ) 
 7.3.[ADDRESS_846632] – Visit 8 (14 days after Visit 6 ) 
 
Approximately two weeks after the second film insertion  at Visit 6, the study team will contact 
[CONTACT_633996] , comfort with the film,  
and any concerns . Participants who prefer to complete these procedures in -person may elect to 
do so. Participants who report AEs o r otherwise express concerns may be asked to come in for 
an Interim Visit, if willing, to conduct additional counseling and/or testing as needed.  
 
 
MATRIX -002, Version 1.0          24 May 2023 20 Table 7: 6- week  Telephone Contact – Visit 8 (14 days after Visit 6 ) 
6-week  Telephone Contact  – Visit 8 (14 days after Visit 6 )  
Component  Procedures  
Administrative and Regulatory 
 • Review/update locator information  
• Provide reimbursement  
• Schedule next visit/contact  
[CONTACT_625111] /Counseling  • Brief behavioral assessment (concerns and comfort with film use) 
• Protocol counseling*  
Clinical  • Review/update medical and menstrual history  
• Review/update concomitant medications  
• AE assessment  
• Provide available test results  
*If indicated and/or per local standard of care  
 
7.3.6  8-week  Visit – Visit 9 (28 days after Visit 6 ) 
 
At least f our weeks after the second film insertion  at Visit 6 , participants will come to the clinic 
for acceptability and safety evaluation for the second  film, and the cl inician will remove any visible 
film. Participants will be asked to provide a urine sample for a UPT, undergo HIV/STI testing and 
a pelvic examination, and complete  an interviewer -administered acceptability questionnaire about 
the film and a social harms and benefits assessment . This visit will constitute the Early 
Termination Visit.  
 Table 8: 8- week  Visit – Visit 9 (28 days after Visit 6 ) 
8-week Visit  – Visit 9 (28 days after Visit 6 )  
Component  Procedures  
Administrative and Regulatory 
 • Review/update locator information  
• Provide reimbursement  
• Confirm  permission to contact [CONTACT_633997] (subset)  and 
invite per site Sexual Partner Contact [CONTACT_633998]  
• Schedule next visit/contact  
[CONTACT_625111] /Counseling  • HIV pre - and post -test counseling  
• HIV/STI risk reduction counseling  
• Protocol counseling  
• Follow -up b ehavioral questionnaire (acceptability and product use 
experiences ; intravaginal practices and sexual activity ) 
• Social harms and benefits assessment  
• Conduct participant IDI (subset)a 
Clinical  • Review/update medical and menstrual history  
• Review/update concomitant medications  
• Perform targeted physical examination * 
• Perform pelvic examination with speculum  
• AE assessment  
• Treat or prescribe treatment for RTI/UTI/STIs*  
• Provide available test results  
Laboratory  Saliva  • HIV test(s) (only at sites with CLIA  certification ) 
Urine  • Urine pregnancy test  
• Urine dipstick/culture*  
 
 
MATRIX -002, Version 1.0          24 May 2023 21 8-week Visit  – Visit 9 (28 days after Visit 6 )  
Component  Procedures  
Blood  • HIV test(s) (not required for sites that conduct  saliva testing)  
• CBC  
• Serum creatinine  
• AST/ALT  
Pelvic  • NAAT for GC/CT /TV 
• Saline/KOH wet mount for candidiasis and/or BV*  
• Vaginal Gram stain  
• Vaginal swab(s) for microbiota  
• Vaginal pH  
Study Product /Suppl ies • Offer male condoms  
*If indicated and/or per local standard of care ; a At or after Visit 9 , before Visit 10  
 
A subset of up to 35  participants  will be purposively selected to complete a single explanatory IDI 
to provide further insight on their  experiences using the placebo film and behaviors relevant to 
the study endpoints.  The IDI Visit may occur on the same day as Visit 9 if agreed upon by [CONTACT_2416](s) and the study staff or may be scheduled up until Visit 10. Participants selected for 
the sexual partner subset  IDI will be asked to confirm permission to contact [CONTACT_633999] – if confirmed – the sexual partner will be invited per site Sexual Partner Contact [CONTACT_633998] . 
 7.3.[ADDRESS_846633]/Study Exit Visit – Visit 10 (7 days after Visit 9 ) 
 The Final Telephone Contact  [CONTACT_634000]. The study team will contact [CONTACT_634001] . Participants who prefer to complete these procedures in -
person may elect to do so.  This visit constitutes the Study Exit Visit (SEV)  and
 will serve as a final 
safety assessment . 
 
Table 9: Final Contact/SEV  – Visit 10 (7 days after Visit 9 ) 
Final Contact /SEV  – Visit 10 (7 days after Visit 9 ) 
Component  Procedures  
Administrative and Regulatory  • Review/update locator information  
• Provide reimbursement  
Clinical  • Review/update medical and menstrual history  
• Review/update concomitant medications  
• AE assessment  
• Provide available test results  
 
7.3.8  Sexual Partners – IDI Visit  
 
Up to  30 sexual partners will be screened and enrolled to take part in a single IDI within one 
month of their participant partner’s  Visit [ADDRESS_846634] sexual partners 
will be confirmed at Visit 9 , and – if confirmed – sites will contact [CONTACT_634002]/or local IRB/IEC guidelines . Participants may change their decision about their sexual 
partners’ involvement at any time during the study . Selection of sexual partners to invite for an 
 
 
MATRIX -002, Version 1.0          24 May 2023 22 IDI will be purposive so that characteristics/experiences of the enrolled study participant, use of 
film A or B, study site, and a breadth of perspectives and experiences are represented. Selection 
criteria and procedures will be further describ ed in the MATRIX -002 SSP Manual . The IDI will 
include the following  topi[INVESTIGATOR_1102] : 
• Disclosure/knowledge/un derstanding of clinical study , participant’s involvement in 
MATRIX -002, protocol restrictions on sexual activity in Month 1, and study product. 
• Experiences of sex with clinical study participant during the time they were using study 
product . 
• Perspectives and attitudes regarding monthly vaginal film use for HIV prevention . 
 
Table 10: IDI Visit with Sexual Partner Subset 
IDI Visit with Sexual Partner Subset  – Screening and Enrollment Procedures  
Component  Procedures  
Administrative and Regulatory 
  • Confirm eligibility  
• Obtain written informed consent  
• Assign a unique PTID Number  
• Collect demographic data  
• Collect locator information  
• Provide reimbursement for study visit  
Behavioral  • Administer brief behavioral questionnaire  
• Conduct sexual partner IDI b 
 b Within one month of  participant Visit [ADDRESS_846635] 
use will cease, and the participant will be considered terminated from the study. An Early Termination Visit will be conducted, if the participant is willing  (see Section 7.3.6 ). Please 
reference the MATRIX -[ADDRESS_846636] use  will cease , follow -up visits and procedures will be discontinued, and the participant 
will be considered terminated from the study. An Early Termination Visit will be conducted, if the 
participant is willing  (see Section 7.3.6). Please reference the MATRIX -[ADDRESS_846637] their remaining  study follow -up visits and procedu res discontinued . 
Participants will, however, be asked to complete an Early Termination Visit, if willing  (see Section 
7.3.6). In the event study follow -up is continued, participants will have the protocol -specified 
visits through SEV. Sites should contact [CONTACT_634003].   
 
Participants who permanently discontinue study product use due to an adverse event ( AE) should 
continue to be followed in the study, if willing, until resolution (return to baseline) or stabilization of the AE is documented.  
 7.5 Interim Visits/Contacts 
 
Interim visits /contacts  (i.e., between regularly scheduled visits) may be performed as needed 
(e.g., participant reports an AE  or social harm ) at any time during the study, and any visit/contact  
[CONTACT_634004]. All interim contacts and visits will be documented in 
participants' study records. Refer to the MATRIX -002 SSP Manual for additional details.  
 7.6 Behavioral Evaluations  
 
The study will address questions related to the primary, secondary, and exploratory objectives of 
acceptability, usability , and social harms and benefits,  and both participants’ and sexual partners’  
attitudes towards and experiences with the vaginal film. The study will assess film use facilitators 
and challenges experienced by [CONTACT_4317], from the perspective s of both the participants and a 
subset of sexual partners. The study will also explore participants’ and sexual partners’ views on acceptable approaches to support study product adherence. These questions will be assessed via behavioral questionnaires and IDIs conducted by [CONTACT_138207]/facilitators. In addition, the 
study aims to gain further insight on:  
 
• Product insertion  
• Attitudes towards and experiences with using the vaginal film  
• Perspectives on any changes in vaginal environment  
• Comparisons between the two study products and comparisons to existing HIV prevention 
options  
• Factors related to future willingness to use/recommend  the vaginal film 
• Sexual partner attitudes towards and experiences with the vaginal film, and their perspective of participant’s attitudes and experiences  
 
Additional questions and probes will be designed to delve further into the social and cultural 
norms that may play a role more broadly in product use. SMS or a phone call 24- [ADDRESS_846638] these behaviors  on the appropriate CRF . 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 24 7.6.1  Quantitative Behavioral Assessments  
 Participant attitudes and behaviors will be assessed throughout the study period using multiple 
data collection methods. Behavioral questionnaires at enrol lment and during follow -up will 
measure key dimensions of acceptability perti nent to the vaginal film in its current phase of 
development alongside women’s experiences in using the film during the study. In addition, 
behavioral questionnaires will measure vaginal practices, contraceptive use, HIV prevention 
behaviors, sexual behavior and relationship factors. These questionnaires  will be used to assess  
factors correlated with placebo vaginal film acceptability and use experiences.  Additionally, 
quantitative questionnaire data will be complemented by [CONTACT_634005], and through IDIs with subsets of participants and sexual partners.  
 Table 11 outlines a summary of the assessment methods that will be used and the specific 
components of acceptability that will be assessed , informed by [CONTACT_634006]. al.
19  
 
 Table 11: Summary of behavioral assessments  
Assessments and Timepoints   Acceptability components measured  
Baseline  assessment  
(Visit 2 ) Affective attitude, burden, opportunity costs, 
barriers/benefit s 
Follow -up phone/SMS contacts  
(Visits 3 -5, 7-8) Concerns and comfort with film use  
Follow -up assessments   
(Visits 6 and 9)  Affective attitude, burden, opportunity costs, 
overall  satisfaction , usability, appropriateness, 
preferences, perceived barriers/benefits  
Social harms and benefits assessment 
(Visit 9)  N/A 
Participant IDI 
(At or after Visit 9 , before Visit 10 ) Affective attitude, burden, satisfaction, usability, 
appropriateness, perceived barriers/benefits  
Sexual partner IDI 
(Within one month of Visit 9) Affective attitude, burden, satisfaction, usability, 
appropriateness, perceived barriers/benefits  
 7.6.[ADDRESS_846639] at Visit 9 or sc heduled after the visit and before 
study exit (Visit 10). Additionally, a subset of sexual partners of participants will be purposively 
selected to participate in an IDI, which will take place within approximately one month of Visit [ADDRESS_846640] the vaginal film as a future HIV prevention option. We will also explore sexual partner 
views on the vaginal film and their perceptions of and experience with the film during sexual 
activity.  IDIs will be conducted separately with participants and their sexual partners to assess 
these topi[INVESTIGATOR_1102]. IDIs will include, but not be limited to, the following topi[INVESTIGATOR_1102]:  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 25 • Descriptions of film insertion practices  
• Main challenge(s) encountered with film use, especially during sex  
• Potential changes to the film  
• Other factors (e.g., situational, relationship, trial- specific, social/cultural/economic, sex 
and menstruation related, vaginal practices ) influencing film acceptability and use 
experience  
• Sexual p artner attitudes towards and experiences with the vaginal film, and their 
perspective of participant’s  attitudes and experiences  
 
Semi-structured IDI guides will be developed by [CONTACT_634007]. Guides  will contain key research questions relating to the main topi[INVESTIGATOR_633959]. Interviews and discussion sessions will be audio -recorded  and 
transcribed.  7.7 Protocol Adherence Counseling  
 Participants will receive protocol  counseling upon enrollment into the study (Visit 2) and at Visit 
[ADDRESS_846641] use and practices,  and 
behavioral restrictions during study participation  as specifi ed in Section 6.7. 
 
7.8 Clinical Evaluations and Procedures  
 
Physical Examination  an d Medical History  
The full physical examination will include the following assessments: 
• Vital signs  
o Blood pressure  
• Measurements of weight and height  
• General appearance  
• Cardiac exam  
• Respi[INVESTIGATOR_237245]  
• Abdomen   
 
Participants will be asked about medications/therapi[INVESTIGATOR_633960], including Screening . Study 
staff will ask about adverse events at all visits beginning at  Enrollment . A full physical examination 
will be completed by a clinician at Screening. Thereafter,  a targeted physical examination will be 
performed to assess any complaints or symptoms with which the participant presents at the follow -up visits as clinically indicated. 
 
Pelvic E
xamination 
Pelvic exams will be performed using visual inspection of external genitalia and using a speculum for examination of the cervix and vagina, assessment of film persistence , and insertion of film (if 
 
 
MATRIX -002, Version 1.[ADDRESS_846642] two attempts). Bimanual exam may be performed as needed (required at 
Screening Visit). Pelvic exams will be conducted at Screening, Enrollment, and Visits 6 and 9  for 
vaginal microenvironment specimen col lection  and as indicated based on participant reports. 
Cervicovaginal fluid (CVF) will be collected using swabs.  
 
Additional clinical assessments /procedures may be performed at the discretion of the examining 
clinician in response to symptoms or illnesses present at the time of the exam /procedure. 
 
7.9 L aboratory Evaluations  
 
Local Laboratory  
• Saliva ( only at sites with CLIA  certification ) 
o HIV test(s)  
 
• Urine 
o Urine pregnancy test  
o Urine dipstick/culture  (as indicated, per local standard of care)  
 
• Blood  
o HIV test(s)  (not required  for sites that conduct  saliva testing)  
o CBC 
o Serum creatinine  
o AST/ALT 
o Syphilis serology  
 
• Pelvic  
o NAAT for GC/CT /TV 
o Pap test (if indicated [if participant is unable to provide documentation of a normal  
Pap test within 3 years prior to enrollment ]) 
o KOH wet mount for candidiasis and/or BV  (if indicated)  
o Vaginal pH  
 
Designated Laboratory  
• Blood  
o Plasma for archive  
 
• CVF 
o Gram Stain for Nugent Scoring  
o Microbiota  
 
Only Local Laboratory test results will be provided to the participant. Once all required study 
analyses of collected specimens are complete, any remaining sample s may be shipped to 
Pi[INVESTIGATOR_32887]/MWRIF for use in study -related quality assurance and quality control testing. If study samples 
will be used for assay validation or proficiency testing that is not study related, all participant 
identifiers (PTID) will be removed from the samples prior to use. Specimens obtained from 
participants who do not consent to long term storage will not be used for assay validation or proficiency testing purposes  and will be destroyed when all protocol -specified testing has been 
completed . 
 
 
MATRIX -002, Version 1.0          24 May 2023 27  
7.10  Specimen Management  
 Study sites will adhere to the standards of good clinical laboratory practice, in accordance with the MATRIX -002 SSP Manual and site SOP for proper collection, processing, labeling, transport, 
and storage of specimens. Specimen collection, testing, and storage at the site laboratories will 
be documented when applicable using the Laboratory Data Management System (LDMS) . In cases 
where laboratory results are not available due to administrative or laboratory error, or
 out of 
range and the site IoR/designee determines  reasonable to repeat , the site is permitted to re -draw 
specimens. No genetic testing (limited or genome -wide) is planned on leftover samples that are 
stored for the purposes of future research.  
 
7.11  Laboratory Oversight  
 All laboratories p articipating in this study will adhere to MATRIX’s Laboratory Policy 
(www.matrix4prevention.org). 
 
7.[ADDRESS_846643] with 
contaminated needles, blood, and blood produc ts, appropriate blood and secretion precautions 
will be employed by [CONTACT_43613][INVESTIGATOR_633961] 
(CDC), National Institutes of Health (NIH) , and other applicable national regulatory authorities . 
All biological specimens will be transported using packaging mandated by [CONTACT_625113] (CFR) [ADDRESS_846644] be transported according to instructions detailed in the International Air Transport Association (IATA) Dangerous Goods Regulations. Biohazardous waste will be contained according to institutional, transportation/carrier, and all other applicable regulations.  
 
 
8 ASSESSMENT OF SAFETY 
 8.1 Safety Monitoring  
 
Site IoRs /designees  are responsible for continuous close safety monitoring of all study 
participants, and for alerting the Protocol Team if unexpected concerns arise. A sub -group of the 
Protocol Team, including  the Protocol Co- Chairs , Protocol Safety Physician, Clinical Research 
Manager(s) (CRM), and Pi[INVESTIGATOR_32887]/MWRIF r epresentatives will serve as the PSRT. The Clinical Data 
Manager(s) (CDM) prepares routine AE and clinical data reports for review by [CONTACT_111153], which 
meets via conference call  approximately once per month or more frequently as needed 
throughout the period of study implementation to review safety data, discuss product use management, and address any potential safety concerns.  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 28 8.2 Clinical Data and Safety Review  
 A multi -tiered safety review process will be followed for the duration of this study. The site 
IoRs/designees  are responsible for the initial evaluation and reporting of safety information at the 
participant level and for alerting the PSRT if unexpected concerns arise. Participant safety is also 
monitored through a series of routine reviews conducted by [CONTACT_495805] (if applicable) study 
sponsors. Additional reviews may be conducted at each of these levels as dictated by [CONTACT_634008].   
The CDM(s)  will rev iew incoming safety data on an ongoing basis. Events identified as 
questionable, inconsistent, or unexplained will be queried for verification. To ensure prompt 
review of AEs of concern (e.g., serious adverse events [ SAE] and Related Grade 3+ AEs), such 
AE reports submitted in the clinical database will be forwarded to the PSRT for review  within 72 
hours of entry . 
 The PSRT will meet approximately every month, or as needed, via conference call to review 
clinical data repor ts generated by [CONTACT_634009](s). The content, format and frequency of the clinical 
data reports will be agreed upon by [CONTACT_634010](s) in advance of study implementation. 
In addition to the routine safety data reviews, the PSRT will convene on an ad hoc  basis to make 
decisions regarding the handling of any significant safety concerns. If necessary,  experts external 
to MATRIX  representing expertise in the fields of microbicides, biostatistics, HIV acquisition and 
medical ethics may be invited to join the PSRT safety review. A recommendation to pause or stop the trial may be made by [CONTACT_634011]/or frequency of AEs has been observed.  
 
The Independent Safety Physician (ISP) will review participant safety data as part of their regular 
reviews (see Section 10.6.1 ), since no Data and Safety Monitoring Board (DSMB) oversight is 
planned for MATRIX -002. These reviews will take place approximately every 3 months, or as 
needed. The ISP  will be an independent investigator (s) with no interest (financial or otherwise) 
in the outcomes of this study. At the time of these reviews, or at any other time, the ISP or PSRT 
may convene a panel (composed of the ISP, PSRT and protocol statistician[s]) to review study 
findings. This panel may recommend that the study proceed as designed, proceed with design 
modifications, or be discontinued.  If at any time a de cision is made to discontinue enrollment 
and/or study product use in all participants, Pi[INVESTIGATOR_32887]/MWRIF will notify [LOCATION_003]ID and (as necessary ) 
relevant regulatory autorities , and Site IoRs /designees  will notify the responsible IRB s/IECs 
expeditiously  per local gui delines . 
 
8.[ADDRESS_846645]. As such, an AE can be an unfavorable or unintended sign 
(including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of an investigational product, whether or not considered related to the product. This definition is applied to all study participants and is applied beginning at the time of 
 
 
MATRIX -002, Version 1.0          24 May 2023 29 enrollment (i.e., once a participant is randomized). The term “investigational products” for this 
study refers to the two placebo vaginal films A and B . 
 Study participants will be provided instructions for contact[CONTACT_634012]. In cases of potentially life-threatening 
events, participants will be instructed to seek immediate emergency care. Where feasible and 
medically appropriate, participants will be encouraged to seek evaluation where a study clinician 
is based, and to request that the clinician be contact[CONTACT_18110]. With appropriate permission of the participant, whenever possible, records from all non -study medical providers 
related to untoward medical occurrences may be obtained and required data elements will be 
recorded on study CRF. All participants reporting an untoward medical occurrence should  be 
followed clinically until the occurrence resolves (returns to baseline) or s tabilizes.  
 
Study site staff will document in source documents and in the study database all AEs reported by 
[CONTACT_133787]. AE severity will be graded per  the DAIDS Table for Grading Adult and Pediatric 
Adverse Events, Corrected Version 2.1, July 2017 and/or Addenda 1 (Female Genital Grading Table for Use in Microbicide Studies  [Dated November 2007]). 
 Asymptomatic BV and asymptomatic candidiasis will not b e reportable AEs  but will be captured 
on the appropriate study CRF.  Bleeding at the time of speculum insertion/removal and/ or 
cervicovaginal specimen collection that is judged by [CONTACT_634013], will not be reportable as an AE.  Bleeding that is judged 
by [CONTACT_634014].  
 For any SAEs that are continuing at a participant’s study exit visit, the IoR/designee must establish  
a clinically appropriate follow- up plan for the AE. At a minimum, the SAE must be re -assessed by 
[CONTACT_464] 30 days after the participant’s study exit visit; additional evaluations also may take place at the discretion of the IoR/designee.  
 
The same approach must be taken for any AEs that are found to have increased in severity to 
Grade [ADDRESS_846646] once within the 30 days after the study 
end date.   
Grade 1 and Grade 2 AEs classified as “related” to study product or procedures still ongoing at 
study exit require follow up by [CONTACT_634015] 30 days of study exit.  
 The PSRT may advise study staff as to whether any additional follow -up may be indicated on a 
case-by-case basis. For AEs that are re -assessed after study exit, information on the status of the 
AE at the time of re -assessment will be recorded in source documents only — no updates should 
be made to AE CRFs based on the re -assessments.  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 30 8.3.2  Serious Adverse Events  
 As per the International Council for Harmonization of Technical Requirements for Pharmaceuticals 
for Human Use Good Clinical Practice Guidance (ICH E6; https://www.ich.org/page/efficacy -
guidelines), SAEs are defined as AEs occurring at any dose  that: 
 
• Results in death  
• Is life-threatening  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Requires inpatient hospi[INVESTIGATOR_633962] : Per ICH SAE definition, hospi[INVESTIGATOR_625084], but is an outcome of the 
event. Thus, hospi[INVESTIGATOR_633963]. The 
following are examples of hospi[INVESTIGATOR_625086]:  
o Protocol -specified admission (e.g., for procedure required by [CONTACT_18113])  
o Admission for treatment of target disease of the study, or for pre- existing condition 
(unless it is worsening or increases in frequency of hospi[INVESTIGATOR_633964])  
o Diagnostic admission (e.g., for a work- up of an existing condition such as 
persistent pretreatment lab abnormality)  
o Administrative admission (e.g., for annual physical)  
o Social admission (e.g., placement for lack of place to sleep)  
o Elective admission (e.g., for elective surgery)  
 
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_3767] a serious  adverse drug experience when, based upon 
appropriate medical judgment, they may jeopardize the participant and may require medical or 
surgical intervention to prevent one of the outcomes listed above.  
 
8.3.[ADDRESS_846647] 
 
Relatedness is an assessment made by a study clinician of whether or not the event is related to 
the study agent. The relationship categories that will be used for this study are:  
 
• Related: There is a reasonable possibility that the AE may be related to the study agent(s) 
• Not Related: There is not a reasonable possibility that the AE is related to the study agent(s)  
 
8.[ADDRESS_846648] discontinued and will be terminated from the study. Please see 
Section 9.7 for additional details.  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 31 8.5 Regulatory Requirements  
 AEs reported on CRFs will be included in reports to the applicable national drug  regulatory 
authorities (DRA)  in accordance with DRA requirements . Site IoRs/designees also will submit AE 
information and any other relevant safety information to their IRB /IEC in accordance with IRB /IEC 
requirements.  
8.[ADDRESS_846649] participant privacy and confidentiality, it is 
possible that participants’ involvement in the study could become known to others and that social harms may result. For example, participants could be treated unfairly, or could have problems being accepted by [CONTACT_69310], partners and/or communities. Social harms that are judged by 
[CONTACT_625122]/designee to be serious or unexpected will be reported to the PSRT and responsible site IRB/IEC according to their individual requirements. In the event that  a participant reports social 
harm, every effort will be made by [CONTACT_634016], and/or referral to appropriate resources for the safety of the participant as needed. 
While maintaining participant confidentiality, study sites may engage their community advisory 
boards (CABs) in exploring the social context surrounding instances of social harm.  To mitigate 
one possible source of social harms, each site will carefully explain to eligible participants the 
potential consequences of enrolling their sexual partner (e.g., disclosure of study involvement and/or film use) prior to contact[CONTACT_634017].  
 
 
[ADDRESS_846650] will be defined as not having the second film inserted at Visit 6 . In general, the IoR/designee has t he discretion to hold study 
product at any time if s/he feels that continued product use would be harmful to the participant or interfere with treatment deemed clinically necessary. Unless otherwise specified below, the IoR/designee should immediately cons ult the PSRT for further guidance on resuming study 
product  during second month of product use (if product discontinuation occurs during first month 
of product use) or progressing to permanent discontinuation of study product  and early study 
termination . The IoR/designee will document all permanent discontinuations on applicable CRFs.  
 
9.[ADDRESS_846651] use by [CONTACT_625122]/designee for any of 
the followin g reasons:  
• A  reactive rapid HIV test.  
• Pregnancy or breastfeeding.  
• Allergic reaction to the study product(s)/drug(s). 
• Reported use of or need for PrEP or PEP . Participants who experience a known or potential 
HIV exposure during study participation or have a recognized risk of exposure and thus 
need PEP or PrEP will have study product permanently discontinued and will be referred for PEP or PrEP initiation. Those  who need PEP will be encouraged to start it as quickly as 
possible and within [ADDRESS_846652] use, these participants will be exite d from the study.  
• Non-therapeutic injection drug use.  
• Participant develops a Grade 3 Related or Grade 4 AE. 
• Participant is unable or unwilling to comply with required study procedures, or otherwise might be put at undue risk to their safety and well -being by [CONTACT_634018], 
according to the judgment of the IoR/designee.  
 The IoR/designee must consult the PSRT on all discontinuations  instituted at their discretion for 
further guidance on resuming product use
 during second month of product use (if product 
discontinuation occurs during first month of product use) or progressing to permanent 
discontinuation  of study product and early stu dy termination . 
 9.[ADDRESS_846653] use. Participants who develop a Grade 3 AE that is judged by [CONTACT_625122]/des ignee to be unrelated to study product may also 
continue product use. If the IoR/designee opts to discontinue study product, the PSRT must be 
notified.    
Grade [ADDRESS_846654] be permanently discontinued and the PSRT notified for participants who 
develop a Grade 3 Related  AE or a Grade 4 AE.  
 9.5 Other Clinical Findings 
 A thorough evaluation of genital complaints is expected in the context of this study; however, 
syndromic management of genital symptoms is acceptable while awaiting laboratory results if such practice is in line with the local standards of care. Observed single dose treatment should 
be provided whenever possible, per clinician discretion. When clinically appropriate, investigators 
should use oral or parenteral medications when at all possible.  
 
Product  use need not be held in the event of an STI/RTI requiring treatment, unless  other 
permanent discontinuation guidelines apply. Should the IoR/designee determine that a 
 
 
MATRIX -002, Version 1.0          24 May 2023 33 permanent discontinuation  is warranted due to an STI or RTI, consultation with the PSRT is 
required.  The IoR/designee should manage STI/RTI per local guidelines or current WHO 
guidelines, available at http://www.who.int/en/.  Test for cure is not required after treatment of 
asymptomatic STIs . 
 
If a suspected finding is reported by [CONTACT_634019], an interim visit may 
be scheduled at the discretion of the site investigator.  
 
9.[ADDRESS_846655] of care. Guidance regarding management and 
referral for participants confirmed to be HIV- positive can be found  in Section 13.10 . Sites will not 
be responsible for paying for HIV- related care.  
 
9.7 Pregnancy  
 Pregnancy testing will be performed at designated study visits and participants will be encouraged 
to report all si gns or symptoms of pregnancy to study staff. The IoR/designee will counsel any 
participant who becomes pregnant according to site SOPs. The IoR/designee also will refer the participant to all applicable  services; however, sites will not be responsible for paying for 
pregnancy- related care.  A participant who becomes pregnant during the course of the study will 
have study  product and all follow- up visits discontinued , and will be  considered  terminated from 
the study as per Section 7.4 .2. 
 9.8 Criteria for Early Termination of Study Participation  
 Participants may voluntarily withdraw from the study for any reason at any time. IoRs/designees also may withdraw participants from the study to protect their safety and/or if they are unwilling 
or unable to comply with required study procedures . Sites mus t notify the PSRT immediately of 
any such instances. Participants also may be withdrawn if Pi[INVESTIGATOR_32887]/MWRIF , [LOCATION_003]ID, MATRIX , 
government or regulatory authorities, including the Office for Human Research Protections 
(OHRP), or site IRB/IEC/DRA  terminate the study prior to its planned end date. Every reasonable 
effort is made to complete a final evaluation of participants who withdraw or are withdrawn from the study prior to completing follow -up (see details regarding the Early Termination Visit in 
Section 7.3.6). Study staff members will record the reason(s) for all withdrawals in participants’ 
study records.  
  
 
 
MATRIX -002, Version 1.0          24 May 2023 34 10 STATISTICAL CONSIDERATIONS  
 10.1  Overview and Summary of Design  
 
MATRIX -002 is a t wo-arm, randomized, multi -center trial to assess acceptability, safety and 
usability of two placebo prototype films when administered vaginally once monthly for two 
months. The primary objective of MATRIX -002 is to assess the acceptability of two placebo film 
types (A and B) administered vaginally once monthly for two months , with the overall goal of 
drawing on findings across primary, secondary and exploratory endpoints to inform design of 
drug- loaded vaginal film . 
 
10.2  Study Endpoints  
 
Primary endpoints  
 
Acceptability  
• Participant ratings of overall satisfaction with using the placebo vaginal films . 
 
Secondary endpoints  
 
Safety  
• Proportion of participants with genitourinary Grade [ADDRESS_846656] . 
 
Usability  
• Proportion of participants with clinically assessed proper insertion (more than half of the vaginal film proximal to introitus). 
 
Exploratory endpoints 
 
Participant acceptability, attitudes and experiences  
• Participant responses to quantitative acceptability assessments and IDI questions. Multiple dimensions will be e xplored, including: 
o Vaginal film attributes, including acceptability ( e.g., ease of insertion, burden, 
perceived effectiveness of film as delivery form) and preferences  
o Experience and comfort with inserted vaginal film (e.g., expulsions, leakage, 
awareness of film during daily activities)  
o Experience during sex and menses  
o Vaginal practices  and concomitant vaginal product use while using vaginal film  
o Perception of sexual partners ’ attitudes towards vaginal film  
o Perceived benefits and concerns/challenges with the vaginal film as a future HIV 
prevention option  
o Interest in using vaginal film as a future HIV prevention option  
 
Sexual partner attitudes and experiences  
• Sexual partner responses during IDI related to:  
o Vaginal film attributes, including acceptability and preferences  
o Perception of participant’s experience using the vaginal film during the study  
 
 
MATRIX -002, Version 1.0          24 May 2023 35 o Physical sensation of the participant’s vaginal film use during sex (as relevant)  
o Perceived benefits and concerns/challenges with the vaginal film as a future HIV 
prevention option  
 
Vaginal microenvironment 
• Change from baseline in vaginal pH following film use during the two study phases (i.e., 
with and without sexual abstinence  requirement).  
• Change from baseline in quantity of selected vaginal microbiota following film use during the two study phases (i.e., with and without sexual abstinen ce requirement).  
• Change from baseline in Nugent score following film use during the two study phases (i.e., with and without sexual abstinence requirement).  
 
Social harms  and social benefits  
• Participant self- report of social harms ( i.e., non- clinical adverse  consequences of study 
participation or product use that may manifest in social, psychological or physical ways ). 
• Participant and sexual partner self -report of social benefits (e.g., positive consequences 
of product use disclosure such as  self-confidence, improved communication with intimate 
partner) resulting from vaginal film use and/or study participation . 
 
10.3  Sample Size and Power C alculations  
 
MATRIX -002 will enroll approximately 100  evaluable participants (i.e., participants who complete 
Visit 6), with approximately 20 participants per site. Participants will be randomized to the 2 study 
arms in a 1:1 ratio, allocating 50 women per arm.  In light of the short study duration and the 
teams’ previous experiences conducting similar research with the study’s target population, we anticipate 5 % LTFU. Therefore, we expect approximately 95 participants (45 -48 per arm) will 
complete the study. A subset of up to 35  study participants will complete an IDI after the 2
nd 
period of film use. We will enroll up to 30 sexual partners to complete an IDI after the participant 
completes the 2nd period of film use.  
 
Note: Replacement participants will be considered in consultation with study leadership  if LTFU 
is higher than expected.  
 Table [ADDRESS_846657] sizes reflecting differences in primary, 
secondary and exploratory endpoints  of the two study products assuming 80% power, two-sided 
α=0.05, varying standard deviations or marginal probabilities , a sample size of 100, and 5% 
LTFU.  
 The primary acceptability endpoint will be measured at Visit s 6 and 9. Secondary endpoints will 
be assessed cumulatively to calculate an overall proportion experiencing the outcome (e.g., AE). The usability of the vaginal film will be determined by [CONTACT_30223] -observed and participant -reported 
measures (e.g., ease of inserti on, number of attempts). Exploratory acceptability endpoints w ill 
be collected at  Visits 6 and 9. In addition, interim data on experience using the placebo vaginal 
film will be collected 24- 72 hours after each film insertion and again 1 week (1
st use perio d only) 
and 2 weeks after each film insertion via SMS or telephone.  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 36 Table 12: Range of potential effect sizes for each endpoint  
 
Continuous outcomes: effect size is difference in means  
Endpoint  Endpoint type  Standard deviation  Minimum detectable 
difference  
Overall satisfaction  
(Likert scale 1 -10) Primary: Acceptability  0.5 – 3.0 0.29 – 1.75 
Likelihood of future use 
(Likert scale 1 -4) Exploratory: Acceptability  0.4 – 1.0 0.23 – 0.59 
Binary outcomes: effect size is risk difference  
Endpoint  Endpoint type  Marginal probabilities  Minimum detectable 
difference  
Adverse events  Safety  0.10 – 0.30 0.24 – 0.29 
 
Qualitative data collection  
Participant experiences: Up to 35 study participants will be purposively selected and invited to 
complete an IDI at Visit 9 or before study exit.  
 Sexual p artner attitude s and experiences: Up to  30 sexual partners will be invited to provide 
insights into their attitudes and experiences through IDIs.  
 An overall sample of 30 IDIs per group is estimated to provide sufficient opportunity to reach 
saturation in the qualitative data on key topi[INVESTIGATOR_1102]. An estimated 6 IDIs per site per group is expected 
to provide sufficient opportunity for any variation on key topi[INVESTIGATOR_633965].  
Participants will be purposively selected for invitation to an IDI based on vaginal film assignment (A or B) and other characteristics or experiences while using the study product. Sexual p artners 
will be purposively selected for invitation to the IDI based on permission provided by [CONTACT_634020], key experiences reported by [CONTACT_634020], and partner interest/availability.  
 
10.4  Randomization Procedures  
 
Participants will be randomized in a 1:1 ratio to the two study arms (Film A or Film B), stratified 
by [CONTACT_3885]. The randomization scheme and procedures will be generated and maintained by [CONTACT_634021].  
 10.[ADDRESS_846658] approximately every three months, or as 
needed. At the time of these reviews, or at any other time, the ISP or PSRT may convene a panel 
 
 
MATRIX -002, Version 1.0          24 May 2023 37 (composed of the ISP, PSRT and protocol statistician[s]) to review study findings. This panel  may 
recommend that the study proceed a s designed, proceed with design modifications, or be 
discontinued. Safety monitoring will be done by [CONTACT_111153].  
 
10.6.2  Primary Analysis(es)  
 
All participants randomized into the study who complete Visit 6 will be included in the primary 
analysis.  
 
When the use o f descriptive statistics to assess group characteristics or differences is required, 
the following methods will be used: for categorical variables, the number and percent in each 
category; for continuous variables, the mean, median, standard deviation, quartiles and range (minimum, maximum). Overall and w ithin-treatment group assessment of the change from the 
baseline measurement to a follow -up measurement will be analyzed using McNemar’s test (for 
categorical response variables) or the paired t- test or Wil coxon signed -ranks test (for continuous 
variables). When us ing formal testing to assess endpoint differences between users of Film A or 
Film B, the following methods will be used: for binomial response variables, chi -square tests and 
logistic regression (or exact testing methods); for continuous variables, t -tests and linear 
regression or nonparametric methods if data are non -Normal. 
 
To assess the adequacy of the randomization, participants in each arm will be compared for 
baseline characteristics including demographics and laboratory measurements using descriptive statistics. Due to the small sample size, formal comparisons will not be done.  
 We will calculate overall estimates for mean satisfaction rating at Visit 9 (Likert 10- point scale) 
and by [CONTACT_634022] A and Film B. We will test for difference 
in mean overall satisfaction rating at V isits 6 and 9 (Likert 10 -point scale)  between Film A and 
Film B using a two -sided t -test (primary endpoint). A nonparametric test will be used if normality 
assumptions are not met.  Analyses will examine sociodemographic and behavioral correlates of 
acceptability rating (i.e., satisfaction)  using linear regression  models with robust standard errors . 
 10.6.[ADDRESS_846659] been exposed to the study products will be included in the 
analysis of safety. Secondary intent to treat analyses may also be performed. To assess 
genitourinary safety, the number and percentages of participants experiencing each safety 
endpoint (see Section 10.2) will be tabulated by [CONTACT_634023]. Each participant will contribute once in each category (i.e., 
only for the highest severity AE for each participant) for the calculation of event rates. Exact 
binomial confidence intervals will be calculated for each safety endpoint for each arm.  
 
Usability  
Usability, participants' ability to insert the film correctly, will be examined by [CONTACT_634024] (and after two 
attempts). This will be examined by [CONTACT_634025]. Changes in ability to insert the film 
correctly will examine this measure at V6 and V 9, by [CONTACT_634025]. 
 
 
 
MATRIX -002, Version 1.[ADDRESS_846660] components of the acceptability framework and related dimensions 
by [CONTACT_30157]. Acceptability endpoints will be summarized by [CONTACT_266099] ( Visits 2 , 6, 
and 9) using descriptive statistics (e.g., frequencies, means), as appropri ate. For example, we 
will examine the level of interest in future use of the film as an HIV prevention option overall and by [CONTACT_30157]. We will also examine responses over time (e.g., ratings of anticipated comfort prior 
to initial film insertion, after fi rst month of film use, and after second month of film use), assessing 
whether they changed with increased experience with product insertion. In addition, analyses will examine sociodemographic and behavioral correlates of acceptability endpoints using linear 
regression models with robust standard errors (for rating outcomes) and using multivariable logistic regression for dichotomous outcomes such as willingness to use (e.g., disinterest in future use). 
 
Participant and S
 exual Partner A ttitudes and E xperiences  
Qualitative data will be audio -recorded, processed, and coded for qualitative analyses, using 
Dedoose or a similar qualitative software. Data coding will be used as a primary analytical 
approach for data reduction, that is, to summarize, extract meaning, and condense the data.21,[ADDRESS_846661] 
for variables that may be related to the missingness mechanism. If missing data rates are higher 
than 10%, covariates that are related to missingness in likelihood -based regression models will 
be included. Sensitivity analyses to assess the potentia l impact of the missing data will also be 
performed. These analyses will include imputing the data under the most extreme scenarios of 
information missingness, such as assuming everyone missing has an extreme value of the missing 
variable, and less informative imputation approaches.  
 
 
11 DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] 
 11.1  Data Management Responsibilities 
 
Data collection tools will be developed by [CONTACT_634009](s) in conjunction with the protocol team. 
Quality control and data integrity are managed manually and systematically with reports and 
 
 
MATRIX -002, Version 1.0          24 May 2023 39 queries routinely generated and provided by [CONTACT_634009](s) to the study sites for verification and 
resolution. As part of the study activation process, each study site will identify all CRFs to be used as source documents. Study CRF data will be entered and managed using R EDCap, a data 
management system compliant with the International Council on Harmonization (ICH) Good 
Clinical Practices (GCP) and US CFR guidelines for electronic data capture.  
 
Transcriptions of interviews will be generated in the field and electronically transferred to RTI  
International using a secure File Transfer Protocol site, where they will be uploaded and managed 
using a qualitative software package. RTI International will act as a hub and manage all qualitative 
data for the study. A convention for file naming will be developed, an d all data will be labeled 
according to this process. RTI International will save all versions of all files on a secure, password -
protected server  in the US . 
 11.2  Source Documents and Access to Source Data/Documents  
 
All study sites will maintain source data/documents in accordance with MATRIX’s Good 
Documentation Practice  (GDP) guidelines (www.matrix4prevention.org). 
 
Each IoR/designee will maintain, and store securely, complete, accurate and current study records throughout the study. In accordance with U.S. regulations, IoRs/designees will maintain all study 
documentation for at least three years after completion of the study.  
 Study records must be maintained on site for the entire period of study implementation.  
Thereafter, instructions for record storage will be provided by [CONTACT_25715][INVESTIGATOR_32887]/MWRIF. No study records may 
be moved to an off- site location or destroyed prior to receiving approval from Pi[INVESTIGATOR_32887]/MWRIF . 
 11.[ADDRESS_846662] quality control and quality assurance procedures in accordance with MATRIX’s Quality Management Plan  (www.matrix4prevention.org) . 
  
12 CLINICAL SITE MONITORING  
 Study monitoring will be carried out by [CONTACT_634026] (ACRO)  for the 
African sites and by [CONTACT_32928][INVESTIGATOR_633966] (ECS- HSR) for the US site . Study monitors will do the following:  
 
• Review informed consent forms, procedures, and documentation . 
• Assess co mpliance with the study protocol, Good Clinical Practices (GCP) guidelines, and 
applicable regulatory requirements (US and non -US), including US Code of Federal 
Regulations (CFR) Title 45 Part 46 and Title 2 Parts 200 and 225. 
• Perform source document verification to ensure the accuracy and completeness of study data. 
• Verify proper collection and storage of biological specimens . 
• Verify proper storage, dispensing, and accountability of investigational study products . 
 
 
MATRIX -002, Version 1.0          24 May 2023 40 • Assess implementation and documentation of  internal site quality management 
procedures . 
 Monitoring visits may be conducted on -site or remotely. Remote visits may include remote source 
document verification using methods specified for this purpose. Remote monitoring visits may be 
performed in place of or in addition to onsite visits to ensure the safety of study participants and 
data integrity.  
 
For on -site visits , the IoR/designee will allow study monitors to inspect study facilities and 
documentation (e.g., informed consent forms, clinic and laboratory records, other source 
documents, CRFs), as well as observe the performance of study procedures. The IoR/designee 
also will allow inspection of all study -related documentation by [CONTACT_634027] , Pi[INVESTIGATOR_32887]/MWRIF , [LOCATION_003]ID, OHRP, IRB/IEC  and other local, US, or international regulatory 
authorities. A site visit log will be maintained at the study site to document all visits.  
  
13 HUMAN SUBJECTS PROTECTIONS  
 Site investigators will make efforts to minimize risks to participants. Participants and study staff 
members will take part in a thorough informed consent process. Before beginning the study, 
IoRs/designees will have obtained IRB /IEC approval. IoRs/designe es will permit audits by [CONTACT_523615], 
OHRP, M ATRIX , IRB/IEC, and other local, US, or international regulatory authorities or any of 
their appointed agents.  
 Changes to this protocol may be implemented by [CONTACT_634028]/IEC approval, if those changes are required to eliminate apparent immediate hazards to the study participant ; see 45 
CFR 46.108(a)(3)(iii) under the 2018 Requirements (https://www.ecfr.gov) . These changes must 
be documented as Protocol Deviations and reported to the Protocol Team and IR B/IEC as soon 
as possible ; see ICH E6(R2), Good Clinical Practice, Section 4.5.4  (https://www.fda.gov/science -
research/clinical -trials-and-human- subject -protection/ich -guidance- documents ). In the event of a 
public health emergency, investigators should adhere to the recommendations of their local institutions, IRB/IEC and local health departments. When conflicts exist between local directives, MATRIX ,
 Protocol Team and/or [LOCATION_003]ID policies or guidance, sites should follow the requirement 
that is most protective of study participants and site staff.  
 13.1  Institutional Review Boards/Ethics Committees  
 
Each participating institution will be  responsible for assuring that this protocol, the associated 
site-specific informed consent forms (ICF), and study -related documents (such as participant 
education and recruitment materials) are reviewed by [CONTACT_1201]/IEC  responsible for oversight of 
research conducted at their study site  and by [CONTACT_634029] . Any amendments to the 
protocol must be approved by [CONTACT_634030] /IECs  and (if applicable) national DRA prior to 
implementation.  
 Subsequent to the initial review and approval, the responsible IRB s/IECs must review the study 
at least annually. Each IoR/designee will make safety and progress reports to the ir IRB/IEC and 
(if applicable) to their national DRA at least annually and within three months after study 
 
 
MATRIX -002, Version 1.0          24 May 2023 41 termination or completion. These reports will include the total number of participants enrolled in 
the study, the number of participants who completed the study, all changes in the research 
activity, and all unanticipated problems involving risks to human subjects or others. In addition, 
the results of all safety  reviews of the study will be provided to the IRBs /IECs  and (if applicable) 
national DRA . 
 
13.[ADDRESS_846663] the protocol and the protocol consent forms approved, as appropriate, by [CONTACT_634031]/IEC and any other applicable regulatory entities . Upon receiving final approval, sites will 
submit copi[INVESTIGATOR_633967] /amendment documents (i.e., IRB/IEC approval letters  with 
a detailed list of approved documents, approved ICF documents, etc.)  to the MATRIX Clinical 
Trials Hub Regulatory team . 
 The MATRIX CRM(s)  will review the submitted document packet to ensure receipt of all required 
protocol/amendment documents prior to study activation at the sites . Sites will receive a Study 
Activation Notification from the MATRIX CRM(s)  that indicates successful completion of the 
protocol readiness  process. A copy of the Study Activation Notification should be retained in the 
site's regulatory files.  
 Upon receiving final IRB/ IEC and any othe r applicable approval(s) for an amendment, activated 
sites should implement the amendment immediately  but are still required to submit copi[INVESTIGATOR_633968] . 
 13.3  Study Coordination  
 Study implementation will be directed by [CONTACT_3181], which may not be amended without prior written approval from the Protocol C o-Chairs and Protocol Team representatives from MATRIX , 
Pi[INVESTIGATOR_32887]/MWIF  and [LOCATION_003]ID . Study implementation will also be guided by a common SSP Manual that 
provides further instructions and operational guidance on conducting study visits; data and forms processing; specimen collection, processing, and shippi[INVESTIGATOR_007]; AE assessment, management an d 
reporting; dispensing study products and documenting product accountability; and other study 
operations. Standardized study- specific training will be provided to sites by [CONTACT_634032](s)  
and other designated members of the Protocol Team.  
 
Close coordi nation between protocol team members is necessary to track study progress, respond 
to queries about proper study implementation, and address other issues in a timely manner. The PSRT will address issues related to study eligibility and AE management and re porting as needed 
to assure consistent case management, documentation, and information -sharing across sites. 
Rates of accrual, adherence, follow -up, and AE incidence will be monitored closely by [CONTACT_634033] b. 
 
 
 
MATRIX -002, Version 1.[ADDRESS_846664] problems in their partner relationships associated 
with study- required abstinence. The study staff will provide counselling and referral for support 
and/or care where required.  
 
Participation in clinical research includ es the risk of loss of confidentiality  and discomfort with the 
personal nature of questions when discussing sexual behaviors . Study staff will make every effort 
to protect participant privacy and confidentiality during the study visits. V isits will take place in 
private, however, it is possible that others may learn of an individual’ s study participation and, 
because of this, may treat them unfairly or discriminate against them.  
 
Phlebotomy  
Participants may feel discomfort or pain when their blood is drawn. They may feel dizzy or faint 
or develop a bruise, swelling, small clot, or in rare cases, an infection where the needle goes into their arm.  
 
Pelvic  E
xamination and Procedures  
Participants may feel discomfort, pain or pressure during the exam and wh en specimens are 
collected. They may have a small amount of vaginal bleeding or spotting which should stop shortly 
after the exam.  
 
CVF C ollection  
Collection of CVF  may cause discomfort or pressure in the vagina or genital area.  
 
Risks Associated with Va ginal Films  
Participants may feel discomfort, itching, irritation, and vaginal discharge during film use. Based 
on previous film studies, these experiences are not prevalent. 
 
Risks Associated with P lacebo Excipi[INVESTIGATOR_633969] (GRAS) and /or have a history 
of pharmaceutical use.  
 
Social Harms  
Although study sites will make every effort to protect participant privacy and confidentiality, it is 
possible that involvement in the study could becom e known to others and that social harms – 
 
 
MATRIX -002, Version 1.0          24 May 2023 43 non-medical adverse consequences – may result. For example, participants could be treated 
unfairly, or could have problems being accepted by [CONTACT_69310], partners and/or communities.  
 
13.4.[ADDRESS_846665] benefit. Participants and others may benefit 
in the future from information learned from this study. Specifically, information learned in this 
study may lead to the development of safe and effective interventions to prevent HIV acquisition and transmission. Participants also may appreciate the opportunity to contribute to the field of 
HIV prevention.  
 
Participants will receive HIV/STI risk reduction counseling, HIV and STI testing, and physical and 
pelvic exam s. Participants will be provided STI treatment free of charge, and referrals may be 
provided  if needed . For other medical conditions identified as part of the study screening and/or 
follow -up procedures, participants will be referred to other sources of care available in their 
community. Some participants  may have the opportunity to access expedient treatment and 
decreased morbidity due to early diagnosis and treatment of abnormalities identified during tests, examinations and referrals.  
 13.[ADDRESS_846666] document the informed consent process in 
accordance with MATRIX’s GDP guidelines (www.matrix4prevention.org). Participants will be 
provided with copi[INVESTIGATOR_625088].   
 In addition to the ICF, the Protocol Team will work with study staff and community representatives 
to develop appropriate materials about the study and a standar dized approach to the informed 
consent process to be implemented at study sites, which will be detailed in the MATRIX- 002 SSP 
Manual.   The informed consent process will cover all elements of informed consent required by [CONTACT_18125]. In addition, the process specifically will address the following topi[INVESTIGATOR_633970]:  
 
• The need to practice safer sex behaviors . 
• Both study products are placebos that provide no protection against HIV acquisition, STIs, 
or pregnancy . 
• The importance of ad herence to the study visit and procedures schedule. 
• The potential medical risks of study participation (and what to do if such risks are 
experienced) . 
• The potential social harms associated with study participation (and what to do if such harms are experienced) . 
• The limited benefits of study participation . 
 
 
MATRIX -002, Version 1.0          24 May 2023 44 • The distinction between research and clinical care . 
• The right to withdraw from the study at any time . 
 Furthermore, participants who agree to have their sexual partner contact[CONTACT_634034] -002 
will be asked to read and sign an additional “Permission to Contact” form before the partner is 
invited to enroll. This form will explain that the participant gives the study staff permission to 
contact [CONTACT_634035] ’s experiences using the vaginal film. This 
means the sexual partner will be aware of the participant’s study involvement and use of the vaginal film. Sites will contact [CONTACT_634036]/or local IRB/IEC 
guidelines . Sexual partners who agree to enroll in the study will provide written informed consent 
prior to completing the IDI.  
 
13.[ADDRESS_846667] protected access systems. Forms, lists, 
logbooks, appointment books, and any other listings that link participants’ ID numbers to 
identifying information will be stored in a separate, locked file in an area with limited access. Participants’ study information will not be released without their written permission, except as necessary for review, monitoring, and/or auditing by [CONTACT_716]:  
 
• Representatives of the US Federal Government, including the US OHRP, [LOCATION_003]ID, and/or contractors of [LOCATION_003]ID , and other local, US, or international regulatory authorities  
• ACRO and ECS-HSR 
• Representatives of Pi[INVESTIGATOR_32887]/MWRIF  
• MATRIX designees/representatives  
• Study staff  
• Site IRB s/IECs 
 
13.[ADDRESS_846668] discontinuation will be implemented. Follow- up visits  and procedures will be discontinued, 
and the participant will be considered terminated from the study. An Early Termination Visit may 
 
 
MATRIX -002, Version 1.0          24 May 2023 45 be completed and data collected per Section 7.4.2. During the informed consent process, 
participants will be informed that the placebo vaginal film is not a method of contraception and 
the effects of the placebo vaginal film  on a developi[INVESTIGATOR_19241].  
 
13.7.2  Children  
 
The US NIH has mandated that children, defined as younger than 18 years old, be included in 
research trials when appropriate. This study meets “Justifications for Exclusion” criteria for younger children as set forth by [CONTACT_18121] (specifically, “insufficient data are available in adults to 
judge potential risk in children” and “children should not be the initial group to be involved in 
research studies”). As such, this study does not plan to enroll children . 
 13.8  Compensation  
 Pending IRB/ IEC approval, participants will be compensated for time and effort in this  study, 
and/or be reimbursed for travel to study visits and time away from work. Site -specific 
reimbursement amounts will be determined per local IRB/IEC /DRA guidelines and will be specified 
in the study ICFs of each individual site.  
 If a participant becomes ill or injured as a result of participation in this trial, medical treatment 
for the adverse reaction or injury will be provided appropriately. The site staff will refer the 
participant for ongoing treatment for the injury, if needed. Where required, clinical trial insurance 
purchased by [CONTACT_634037]. An HIV infection that occurs during 
the course of the trial will not be considered an injury or illness caused by [CONTACT_634038] . 
 
13.[ADDRESS_846669] positive for HIV after Enrollment Visit, follow- up procedures will be performed as per Section 7.4.1. 
 13.11  Study Discontinuation 
 This study may be discontinued at any time by [CONTACT_523615], MATRIX, Pi[INVESTIGATOR_32887]/MWRIF , the OHRP, other 
local, US or international regulatory authorities, or site IRB/I EC. 
  
[ADDRESS_846670], or manuscript will be submitted by [CONTACT_634039] , MATRIX and Pi[INVESTIGATOR_32887]/MWRIF 
for review prior to submission.  
  
15 APPENDICES 
  
 
 
MATRIX -002, Version 1.0          24 May 2023 47 APPENDIX I:  SCHEDULE OF STUDY VISITS AND EVALUATIONS   
SCR   
Visit 1             ENR         
Visit 2  
(Day 0) 24-72 hr 
Contacts 
Visits 3 &7 
(1-3 days 
after V2&V6 ) 1- & 2-wk 
Contacts 
Visits 4-5 
(7&14 days 
after V2 ) 4-wk Visit 
Visit 6 
(28 days 
after V2 ) 6-wk 
Contact  
[CONTACT_4838] 8 
(14 days 
after V6 ) 8-wk 
Visit 
Visit 9 
(28 days 
after V6 ) Final 
Contact  
[CONTACT_4838] 10 
(7 days 
after V9 ) 
ADMINISTRATIVE AND REGULATORY  
Obtain/review informed 
consent for screening & /or 
enrollment (sites may split 
screening and enrollment consent if requested/ 
required by [CONTACT_1744]/IEC ) X X  
     
Assign a unique PTID  X        
Collect demographic and 
background information  X        
Assess/confirm eligibility  X X       
Randomization   X       
Confirm  permission to 
contact [CONTACT_634040] (subset)     
   X  
Collect/update/review 
contact/locator information  X X  X X X X X 
Provide reimbursement  X X X X X X X X 
Schedule next visit/contact  * *  X X X X  
COUNSELING  
HIV pre - and post -test 
counseling  X X   X  X  
HIV/STI risk reduction 
counseling  X X   X  X  
Protocol counseling  X X  * X * X  
BEHAVIORAL  
Review instructional 
materials   X   X    
Behavioral q uestionnaire (s)  X  
(pre & post 
insertion)    X  X  
Brief behavioral 
assessment (c oncerns and 
comfort with film use )   X X  X   
Social harms and benefits 
assessment        X  
IDI – subset of participants        Xa  
IDI – sexual partners        Xb  
CLINICAL  
Collect /update/review  
medical and menstrual 
history  X X  
X X X X X 
Collect/update/review 
concomitant medications  X X  X X X X X 
Physical exam (targeted 
after Screening)  X *   *  *  
 
 
MATRIX -002, Version 1.0          24 May 2023 48  
SCR   
Visit 1             ENR         
Visit 2  
(Day 0) 24-72 hr 
Contacts 
Visits 3 &7 
(1-3 days 
after V2&V6 ) 1- & 2-wk 
Contacts 
Visits 4-5 
(7&14 days 
after V2 ) 4-wk Visit 
Visit 6 
(28 days 
after V2 ) 6-wk 
Contact  
[CONTACT_4838] 8 
(14 days 
after V6 ) 8-wk 
Visit 
Visit 9 
(28 days 
after V6 ) Final 
Contact  
[CONTACT_4838] 10 
(7 days 
after V9 ) 
Pelvic exam with speculum  
(including bimanual exam 
at Screening)  X X  
 X  X  
Visual examination by 
[CONTACT_634041]   X  
 X    
Film insertion assessment   X   X    
Provide available  test 
results  X X  X X X X X 
AE assessment   X  X X X X X 
Treat or prescribe 
treatment for RTI/UTI/STIs  * *   *  *  
LABORATORY  SALIVA  
HIV test(s) (only at 
sites with CLIA 
certification ) X X  
 X  X  URINE  
Urine pregnancy test X X   X  X  
Urine dipstick/culture  * *   *  *  BLOOD  HIV test(s)  (not 
necessary for sites that 
perform saliva testing)  X X  
 X  X  
Plasma for archive   X       
CBC X *   *  X  
Serum creatinine  X *   *  X  
AST/ALT  X *   *  X  
Syphilis serology  X        PELVIC  Pap test  ^        
KOH wet mount for 
candidiasis and/or BV  * *   *  *  
Vaginal Gram Stain   X   X  X  
Vaginal swab (s) for 
microbiota   X   X  X  
Vaginal pH   X   X  X  
NAAT for GC/CT/ TV X X   X  X  
STUDY PRODUCT SUPPLY  
Provide vaginal film for 
self-insertion at clinic   X   X    
Clinician insertion of vaginal 
film at clinic ( only if 
participant fail s two 
attempt s)  X  
 X    
Offer male condoms      X  X  
   X Required  
   *If indicated and/or per local standard of care  
   ^ if indicated (if participant is unable to provide documentation of a normal Pap test within 3 years prior to  enrollment)  
     a At or after Visit 9, before Visit 10 
     b Within one month of participant Visit 9 
  
 
 
MATRIX -002, Version 1.0          24 May 2023 49 APPENDIX II:  ALGORITHM FOR HIV TESTING – 
SCREENING/ENROLLING/FOLLOW -UP 
 
START  
2 different  
rapid tests* 
Is this a  
Screening  
Participant  
? 
- / - 
+ / + or + / - or Indeterminate   
+ 
Yes 
 
HIV Confirmation  
Test  
- or Ind eterminate  
No 
Report as  
HIV Uninfected  
Not eligible for  
enrollment  
  *CLIA certified labs may perform [ADDRESS_846671]     
Report as HIV  
Infected  
Consult  
Protocol  
Team  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 50 APPENDIX III:  SAMPLE INFORMED CONSENT FORM (SCREENING, 
ENROLLMENT, LONG- TERM STORAGE AND FUTURE TESTING)  
 
SAMPLE INFORMED CONSENT FORM  
 
MATRIX -002 
Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal 
Films  
 
[LOCATION_003]ID  
 
Version 1.0 
24 May 2023  
 
PRINCIPAL INVESTIGATOR: [SITES TO INSERT ] 
INSTITUTION: [SITES TO INSERT ] 
AFTER HOURS CONTACT [CONTACT_359242]: [SITES TO INSERT ] 
STUDY SITE CONTACT [CONTACT_359242]: [SITES TO INSERT ] 
SHORT TITLE: VALUE Placebo Film Study  
 INFORMED CONSENT  
[
SITES TO INSERT APPROPRIATE GREETING ] You are being invited  to take part in this research 
study because you are a n 18-45-year-old woman in good health. Approximately 100 women  will 
take part in this study across sites in the [LOCATION_002] (US), Kenya, South Africa, and Zimbabwe . 
This study is looking at two placebo vaginal films.  
 
This study is sponsored by [CONTACT_634042]  ([LOCATION_003]ID) and conducted 
by [CONTACT_32928][INVESTIGATOR_9109]/Magee-Womens Research Institute and Foundation ( Pi[INVESTIGATOR_32887]/MWRIF) 
as part of MATRIX: A [LOCATION_003]ID Project to Advance the Research and Development of Innovative HIV Prevention Products for Women. The placebo vaginal films  are supplied by [CONTACT_25715][INVESTIGATOR_32887]/MWRIF . At 
this site, the person in charge of this study is [
SITES TO INSERT ]. 
 KEY INFORMATION  
• The study will assess the acceptability and safety of the two placebo vaginal films. The placebo films do not contain any active medication; the films do not prevent HIV.  
• You would be randomly assigned to one of the two films and asked to use (self-insert) the 
assigned film two times (approximately one month apart). The study involves answering 
questions, undergoing pelvic examinations , and collecting blood and vaginal fluid  samples.   
• You would be in the study for approximately 9 weeks once you are enrolled.  
• The study involves a total of 10 visits/contacts, including in person visits and telephone calls.  
• There may be no benefit to participating.  
• You cannot join this research study if you are living with HIV , pregnant, breastfeeding,  or are 
already taking part in another research study involving drugs, medical devices, vaginal 
products, or vaccines . 
• Taking part in this research study is voluntary. You do not have to participate, and you can 
stop your participation in the study at any time.  
 
 
 
MATRIX -002, Version 1.[ADDRESS_846672] 
complete the screening tests and exams to see if you are eligible. It is important to know that your participation in this research study is your decision and taking part in this study is completely 
voluntary (see You r Rights as a Research Participant/Volunteer for more information).  
 
WHY IS THIS RESEARCH BEING DONE?  
Investigators are studying products that women can use for HIV prevention. Vaginal films are being evaluated as one potential way to deliver anti -HIV drugs into the vagina (in future studies).   
 This study will allow participants to use one of the placebo vaginal films twice during their 
participation. The study will evaluate safety and will collect information on acceptability and use.   
 
Both vaginal fil ms being used in this study are 2 x 2 inch placebo vaginal films  (contain no 
medication) . They are “prototype” films for future studies and will be referred to as Film A and 
Film B. They differ by [CONTACT_7823] . The components of the placebo films being used in this study have 
been used in other products and /or have been generally regarded as  safe.  
 
WHO WILL BE IN THIS RESEARCH STUDY? 
Approximately 100 women who are 18 -45 years old will be enrolled in the study across sites in the 
[LOCATION_002] (US), Kenya, South Africa, and Zimbabwe . 
 DO I HAVE TO BE IN THIS STUDY?  
You do not have to be in this study. You can still get the care you need even if you do not join 
the study. If you join today, you can change your mind later.  
 
WHAT WILL I BE ASKED TO DO IF I JOIN THIS RESEARCH STUDY?   
You will undergo a screening visit to be sure you are eligible and interested. If you are eligible 
and decide to enroll in this study, you will be asked to use (self-insert) one of two placebo vaginal 
films, approximately one month apart. Neither you nor investigators can choose the film you will 
use.  Both placebo films are important to the study.  
 
You must be using an ef fective method of birth control for at least two weeks before  screening 
and agree to continue to use the method throughout the duration of the study to qualify.  
 
At the Enrollment Visit (V2) you will be asked to insert the first vaginal film, undergo evaluations, 
and provide feedback about your experience. During the first month after film insertion, you will 
be asked to abstain from sex and not use anything in the vagina. For example, t his means  no 
sex, fingers, tampon s, menstrual cup s, toys, douches , vaginal medications. If you do not think 
you can agree to this, you should not participate.    Approximately a month later (V6) you will be asked to insert a second film (the same assigned 
film), undergo evaluations, and provide feedback about your exper ience. During the month 
following this [ADDRESS_846673] scheduled follow -up clinic visits and telephone contacts  as detailed below.  
 WHAT WILL HAPPEN DURING THE S TUDY VISITS?  
The study includes a total of ten (10) clinic visits  or telephone contacts , including the Screening 
Visit today. All in-person visits will take place at this clinic. Telephone contacts may be done 
through a phone call or via text message.
 Participants who prefer to complete the telephone 
contacts  in-person may elect to do so.  
 
Study Visit Schedule : 
  
 
 
 
 
Screening Visit (Visit 1) Procedures:  
The procedures done at this visit will let us know if you can join this study and will take about 
[SITES TO SPECIFY TIMEFRAME] .  
 
At the Screening Visit, y ou will: 
• Answer questions related to  
o Demographics: date of birth, race, contact [CONTACT_3031], etc.  
o Medical and menstrual history:  review of any medical problems you may have  
o Medication use: review any medication you take , including start date, dose, etc.  
o Birth control method: you must be using and agree to continue to use an acceptable, 
reliable method throughout the study to qualify  
o Visit questionnaire  
• Undergo counseling  
o HIV/STI (sexually transmitted infection) counseling and how to reduce your risk  
o Abstinence (no sex  and no vaginal product) counseling will be reviewed. This would 
be for the first month, starting at the Enrollment Visit.  
 It is important that you know if you are not currently using an 
acceptable method of contraception , or if you do not think you can 
abstain from vaginal intercourse  or use of vaginal products for the first 
month of film  use, you will not be eligible to participate in this study.  Scr
V1Enr 
V224-[ADDRESS_846674] use  
 ≤[ADDRESS_846675] Film 
Note: phone check visits may be converted to other remote contact [INVESTIGATOR_12183] (e.g., SMS ) or in-person as needed and preferred by [CONTACT_634043] -002, Version 1.0          24 May 2023 53 • Have examinations  
o Physical exam  
o Pelvic exam: a speculum (device inserted in to the vagina) will be used to look at the 
vagina and cervix      
• Have baseline testing:  
o Urine pregnancy test:  If you are pregnant, you will not be able to join  
o HIV test:  [ SITES TO INSERT TYPE OF HIV TEST and LOCAL REQUIRED LANGUAGE ] 
o Blood test: Approxim ately [ SITES TO INSERT VOLUME ] will be collected to look at the 
general health of your blood, basic kidney and liver function, and to screen for syphilis  
o STI test for gonorrhea, chlamydia and trichomonas by [CONTACT_54315] a Q -tip like swab  
o Pap smear:  If you have not had a normal result  within the required period and/or the 
report is not available, you will have a Pap smear performed by [CONTACT_2329] a soft brush to 
collect a sample from your cervix  [SITES TO MODIFY/ADD  AS NEEDED : to screen for 
cervical cancer ]  
o Additional tests may be done if you are having symptoms and as clinically indicated:  urine dip stick/culture and/or microscope exam of vaginal fluid to check for infections  
• Receive test results  
o Results of the tests listed above will be reviewed with you o nce available. Some tests 
results may be available while you are at today’s visit (urine pregnancy test) while others may take up to a week to result (STI testing). The results of these tests will help to determine if you are eligible to participate.  
o If you are diagnosed with a urinary, vaginal (i.e., yeast or BV) or an STI at Screening, 
you will be offered/prescribed treatment   
o If there are other clinically significant findings, for example on your blood test or Pap 
smear, you will be referred for additi onal evaluations and treatment as needed   
• In addition  
o Be provided reimbursement  
o May be tentatively scheduled for an Enrollment Visit within 45 days of Screening
  
 Your menstrual cycle will be considered when scheduling your in -person  visits 
because, ideally, no bleeding should occur around th ose visits  
 It may be necessary to conduct more than one clinic visit to complete all required screening 
procedures  or if a te st needs to be repeated. 
 If you do not join the study, blood and other samples collected at the Screening visit will not be 
kept or used for any tests other than those listed above.  
 
If you are eligible and decide to enroll in the study, there are common study procedures that will 
happen at every in- person visit (V2, V6, V9), including:  
• Review/update your contact [CONTACT_3031], including address and phone number*  
• Review/update your medical and menstrual history*  
• Review/update any medications you are taking/using*  
• Review/update any sexual activity or intravaginal product use  
• Have HIV/STI testing and counseling [
SITES TO MODIFY/ADD  BELOW LANGUAGE AS 
NEEDED ] 
o You will be told your test results as soon as they are available. You will talk with the study staff about the meaning of your results, how you feel about them, and 
learn about ways to prevent HIV and other STIs. Sometimes HIV tests are not 
 
 
 
MATRIX -002, Version 1.[ADDRESS_846676] HIV, you cannot join the study. 
We will refer you  to available sources of medical care and other services you may 
need.  
• Review of any new complaints or side effects once you start using the film*  
• Targeted physical exam, as clinically indicated based on symptoms/complaints  
• Have a urine pregnancy test  
• Have pelvic exam with collection of Q -tip swabs to look at the bacteria in the vagina  
• As needed tests:   
o Repeat blood tests (general health of blood, kidney and liver function)  
o Microscope exam of vaginal fluid to look for yeast or bacteria  
o Urine dip/culture  
• Review of test results*  
• Treatment or referral for abnormal test results as needed  
• Undergo protocol counseling , including HIV/STI risk reduction and contraceptive 
counseling,  as needed*  
• Reimbursement for the study visit/contact*  
• Schedule next visit/contacts*  
 
*These procedures will also be done at the scheduled Telephone Contacts (V4, V5, V8, V10)  
 
Enrollment Visit (Visit 2)  Procedures: 
Your Enrollment Visit (the visit where you enter the study) will take about [SITES TO SPECIFY 
TIMEFRAME ]. You will be randomized to one of two vaginal placebo films at this visit. You will 
receive either placebo film A  or B at this visit, to be self-inserted  at the clinic.  
 
The Enrollment Visit will take place up to 45 days  after your Screening Visit .  
 
In addition to the common study procedures listed above, at the Enrollment Visit, y ou will: 
• Answer questions  
o About the vaginal film  
o About sexual behaviors and risk factors  
o Additional questions about the vaginal film following insertion  
• Undergo counseling  
o Abstinence (refrain from sex and vaginal products) counseling  
• Have examinations  
o Pelvic exam prior to inserting film  
o Visual external (outside) genital exam after insertion of film to check placement  
• Take a blood sample [SITES TO INSERT AMOUNT] . This blood sample will be stored  in 
case there is a question about your test results at a later time . 
• Be randomized to use Film A or B as described above  
• Review instructional materials  
o You will be provided with vaginal film instruction materials  to review prior to inserting 
the film. Study staff will be available to answer any questions you may have.  
• Self-insert the assigned vaginal film (A or B)  
o You will have two attempts to insert the vaginal film  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 55 o If after two attempts, you are having difficulty, a clinician will insert the film  using a 
speculum  
 
24-72-hour Phone Check- in (Visit 3) Procedures:  
This contact [CONTACT_634044] [ADDRESS_846677] . 
 1-week and 2 -week Telephone Contacts (Visits 4 and 5 ) Procedures:  
Your 1-week and [ADDRESS_846678] approximately 7 and 14 days (one 
and two weeks)  following the Enrollment Visit . These telephone contacts  will take approximately 
[SITES TO SPECIFY TIMEFRAME]  to complete.  
 In addition to the common study procedures with Telephone Contacts listed earlier , you will be 
asked about concerns and comfort with film use.
 
 4-week  Visit (Visit 6) Procedures: 
This clinic visit will occur approximately 28 days (4 weeks)  after the Enrollment  Visit and will take 
between  
[SITES TO SPECIFY TIMEFRAME ] to complete.  
 In addition to the common study procedures listed earlier , at this visit y ou will: 
• Answer questions  
o About your experiences using the vaginal film  
o About sexual behaviors and use of vaginal products  
o Additional questions about the vaginal film following insertion  
• Undergo protocol instructions/counseling  
o Reminder there are no restrictions on sex or vaginal product use  
o Explanation of (optional) sexual partner interview component  
 You will be given information to share with your partner to see if your partner 
would be comfortable participating in an intervie w 
 This is optional; if you don’t feel comfortable including or asking your partner to 
participate, you will not be disqualified  
 Your partner would need to sign a separate consent  
o Offer male condoms  
• Have examinations  
o Pelvic exam with removal of any visible film from the first insertion  
o Visual external (outside) genital exam after insertion of second film to check placement  
• Review instructional materials  
o You will be provided with vaginal film instruction materials  to review prior to inserting 
the film. Study staff will be available to answer any questions you may have.  
• Self-insert second vaginal film (A or B) 
o You will be provide d with your previously assigned vaginal film  
o You will have two attempts to insert the vaginal film  
o If after two attempts, you are ha ving difficulty, a clinician will insert the film  using a 
speculum  
 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 56 24-72-hour Phone Check- in (Visit 7) Procedures:  
This contact [CONTACT_634044] [ADDRESS_846679] (Visit 8) Procedures: 
Your [ADDRESS_846680]  approximately 14 days (2 weeks)  after Visit 6. This 
telephone contact  [CONTACT_634045] 
[SITES TO SPECIFY TIMEFRAME]  to complete . 
 In addition to the common study procedures with Telephone Contacts listed earlier , you will be 
asked about concerns and comfort with film use.  
 8-week  Visit (Visit 9) Procedures: 
This clinic visit  will occur approximately 28 days (4 weeks)  after Visit 6 and will take between 
[SITES TO SPECIFY TIMEFRAME]  to complete. 
 In addition to the common study procedures listed earlier , at this visit y ou will : 
• Answer questions  
o About your experiences using the vaginal film  
o About sexual behaviors and use of vaginal products  
o A subset of participants (up to 35 total) will be chosen to do an in- depth interview  
 If chosen, the interview will be performed [
SITES TO SPECIFY MECHANISM:  in 
the presence of one or two MATRIX- 002 research staff members / remotely by a 
behavioral researcher ]  
 Study staff will make every effort to ensure your privacy and confidentiality , and 
information you provide during the interview will not be shared with your partner  
 The interviewer may take notes , and i nterviews will be audio -recorded to make 
sure we record your words exactly how you said them  
 The interview will be focused  on your experience s using the film and behaviors 
during the study and could take up to an hour  to complete  
 The interview may occur during V9 or after up until V10  
• Have examinations  
o Pelvic exam and removal of any visible film  
• Blood test: Approximately [ SITES TO INSERT VOLUME ] will be co llected to look at the 
general health of your blood and basic kidney and liver function  
• Offer male condoms  
• In addition  
o Investigators will ask if you are willing to have your partner contact[CONTACT_634046]- depth interview about your partner’s exp erience while you were in the study.  
This is optional and you should only agree if you (and your partner) feel comfortable.   
o If you agree, you will be asked to [
SITES TO SPECIFY CONTACT [CONTACT_634047]:  provide 
your partner’s  current contact [CONTACT_634048] / provide our contact 
[CONTACT_634049]]  
 
 
 
 
MATRIX -002, Version 1.[ADDRESS_846681] – Study Exit Visit (Visit 10 ) Procedures:  
Your Final Telephone Contact [CONTACT_625134] 7 days (one  week)  following Visit  9. 
This telephone contact  [CONTACT_625135] [SITES TO SPECIFY TIMEFRAME]  to complete.  
 
In addition to the common procedures with Telephone Contacts listed above, you will be asked about  your wellness and any concerns.  This will end your participation in the study.  
 Additional Visits and Procedures In addition to the procedures listed above, it is possible that study clinicians may need to perform 
additional exams or tests, if necessary. For example,  you may be asked to make additional clinic 
visits to perform these exams/tests if you report having s ymptoms and/or other issues , if there 
are abnormal test results, or due to mistakes during the collection, processing and/or shippi[INVESTIGATOR_633971] . These exams/ tests might include the following:  
• Physical and/or pelvic exam  
• Test genital samples  for STIs  
• Test your urine for STIs or other infections  
• Test your blood for STIs  
• Test your blood to check the health of your blood, liver and kidneys  
• Give you treatment or refer you for treatment of STIs or other issues, if needed.  
 
It is important for you to complete  every study visit/contact . If you cannot make a scheduled 
visit/contact , please tell the study staff as soon as possible so that the visit/contact  [CONTACT_634050].  
 
It is important that you remember that at any time during the study, study sta ff can answer any 
questions you may have about the procedures mentioned above or any other aspect of this study.  
 
WHAT IF I BECOME INFECTED WITH HIV? 
The placebo vaginal film s do not contain medications and will not prevent HIV infection. Persons 
living with HIV will not be included in this study. Being in this study will not cause HIV infection. 
However, there is always a chance that you can get HIV through sex or other activities. If you 
become HIV -positive, you will stop using the study product and will stop taking part in this study. 
The study staff will refer you for medical care and other available services. The study does not 
pay for this care. [ SITES TO INCLUDE/AMMEND THE FOLLOWING  IF APPLICABLE : If you are 
interested, study staff will inform you of other available research studies you may be eligible for.]  
 
Depending on local and national health requirements, the study staff may need to report certain 
diseases, including HIV. The reportable diseases at this site are [ SITES TO INSERT ]. We must 
inform the following [ SITES TO INSERT MORE DETAILED INFORMATION REGARDING WHO WILL 
BE INFORMED OF THE REPORTABLE DISEASES ].  [ SITES TO INCLUDE/AMMEND THE 
FOLLOWING ]: Outreach workers from the [ LOCAL HEALTH AUTHORITY ] may then contact [CONTACT_634051]/s, since they also should be tested. If you do not want to inform 
your partner/s yourself, the outreach workers may contact [CONTACT_476], according to the confidentiality 
guidelines of the [ LOCAL HEALTH AUTHORITY ]. 
 WHAT IF I BECOME PREGNANT?  
The placebo vaginal films are not family planning methods and will not prevent pregnancy. We 
do not know what effect the study product(s) have on pregnancy, including any effect on the 
 
 
 
MATRIX -002, Version 1.[ADDRESS_846682] use an 
effective family planning method (e.g., birth control pi[INVESTIGATOR_3353], hormonal -based methods, i ntrauterine 
device [IUD], the patch) other than a vaginal ring  for at least two weeks before screening and 
for the study duration .   
 If you become pregnant during the study, study staff will refer you to available medical care and 
other services. The study does not pay for this care. You will stop using the study product and 
will stop taking part in this study. [
SITES TO INCLUDE/AMMEND THE FOLLOWING  IF 
APPLICABLE : If you are in terested, study staff will inform you of other available research studies 
you may be eligible for.]  
 RISKS AND/OR DISCOMFORTS  
Risks of Blood Draws   
You may feel discomfort or pain when your blood is drawn. You may feel dizzy or faint. You may 
have a bruise, swelling, small clot, or infection where the needle goes into your hand or arm.  
 Risks of Pelvic  Exams   
You may feel discomfort or pressure during the pelvic  exam  and collection  of genital samples . 
You may have a small amount of vaginal bleeding or spotting which should stop shortly after the 
exam.  
 
Risks of Vaginal Films  
You may feel discomfort, itching, irritation, and vaginal discharge during film use.  
 Risks of Placebo Excipi[INVESTIGATOR_633972] /or have a history of 
pharmaceutical use.  
 Risks of HIV and Sexually Transmitted Infection (STI) Testing  
HIV and STI testing may make you feel anxious regardless of the test results. Finding out your HIV status may also cause problems with your family, friends, or partner.  
 
Other Possible Risks  
You may feel embarrassed and/or worried when talking about sexual activities (if you are 
currently sexually active), your living situation, ways to protect against HIV and STIs, and your test results. You can choose not to answer questions at any time. Trained study staff will help 
you with any feelings or questions  you have . 
 We will make every effort to protect your privacy and confidentiality during the study visits. Your 
visits will take place in private. Reports via computer will be stored in computers  that are 
password- protected and will not include personal information that could identify or link 
information to you; only your study ID number will be recorded.  However, i t is possible that 
others may learn of your participation in this study, and becaus e of this, may treat you unfairly 
or discriminate against you. If you have any problems, study staff will talk with you and try to 
help you.  
 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 59 The in-depth interviews with study staff may be performed [SITES TO SPECIFY MECHANISM:  at 
the clinic / remotely ]. The interviews will be audio recorded and questions of a personal nature 
may be asked. Responding to these questions may make you uncomfortable. The audio files will 
be put into writing by [CONTACT_634052]. You should NOT identify anyone in the interviews and any names that might be mentioned on the recording will only be noted in the 
transcript using a generic description. Th e audio files will be stored in computers that are 
password protected . 
 
BENEFITS 
Though you may not experience any direct benefit from participation in this study, information 
learned from this study may help us learn ways to prevent the spread of HIV in the future . Your 
opi[INVESTIGATOR_633973] . 
You will receive medical exams and counseling and testing for HIV and STIs. You will also have tests to check your overall health.  
 
This study cannot give you general medical care, but study staff will refer you to another medical 
provider for care, if needed. Male condoms will be available  at no cost, if  you need them. If you 
are diagnosed  with an STI during the study, you will receive medicine and/or a referral, if you 
need it.   
 NEW INFORMATION  
You will be told about any new information learned during this study that may affect your 
willingness to stay in the study. For example, we will let you know if we learn that the study product may be causing bad side- effects.  
 
WHY YOU MAY STOP USING  THE STUDY PRODUCT  EARLY OR BE ASKED TO LEAVE 
THE STUDY  
You may need to leave the study early without your permission if:  
• The study is cancelled by [CONTACT_634053], Pi[INVESTIGATOR_32887]/MWRIF , the US Office for Human Research 
Protections (OHRP), M ATRIX , the local government or regulatory agency, or the 
Institutional Review Board (IRB)/ Independent Ethics Committee ( IEC). An IRB/ IEC is a 
committee that watches over the safety and rights of study participants.  
• You are not able to keep appointments.  
• Other reasons that may prevent you from completing the study successfully. 
 
The study doctor will ask you to stop using the study products if:  
• You acquire an  HIV infection  (see “If You Become Infected With HIV” section).  
• You become pregnant or are breastfeeding (see “If You Become Pregnant” section).  
• You use  drugs for HIV prevention or to prevent infection after HIV exposure.  
• You use injectable drugs for reasons other than treating disease.  
• You experience a serious adverse event while on study.  
• You f ail to follow study requirements in a manner  judged by [CONTACT_634054] . 
• A study clinician decides that using the study  product  would be harmful to you, for 
example , you have a bad reaction to the vaginal film(s). 
 
 
 
 
MATRIX -002, Version 1.[ADDRESS_846683], we  will ask you to come in for an interim 
visit during which some/all of the procedures scheduled to  occur on Visit 9 will be completed . You 
will then be exited from the study , unless otherwise informed by [CONTACT_464].  
 
ALTERNATIVES TO BEING IN THE STUDY  
This is a placebo study enrolling healthy, adult women. You can cho ose not to participate in this 
study without affecting your care at this or other facilities or your ability to participate in other 
studies.  
 
[SITES TO INCLUDE/AMEND THE FOLLOWING, IF APPLICABLE : You may be able to join other 
studies here or in the community. There may be other places where you can go for HIV counseling 
and testing and family planning. We will tell you about those stud ies and those places if you 
wish.]  
 COSTS TO YOU  
[
SITES TO COMPLETE ACCORDING TO SITE CAPACITY ] There is no cost to you for study visits, 
study products, physical /clinical exams, laboratory tests or other procedures.  We can give you 
treatments for STIs (other than HIV) at no cost  while you are in the study, or we can refer you 
for available treatment.  
 
REIMBURSEMENT  
[SITES TO INSERT INFORMATION ABOUT LOCAL REIMBURSEMENT: ] You will receive [ SITES TO 
INSERT AMOUNT $ XX] for your time, effort, and travel to and from the clinic for each scheduled 
study visit. You may receive [ SITES TO INSERT AMOUNT $XX ] for any extra study visits.  For 
responding to phone calls an d text messages, you will receive up  to [SITES TO INSERT AMOUNT 
$XX]. If you are selected and agree to take part in the in -depth interview, you will receive [ SITES 
TO INSERT AMOUNT $ XX]. 
 
CONFIDENTIALITY We will make every effort to keep your information private and confidential. But we cannot 
guarantee it.  
 
Study visits will take place in private. We will keep the information about your study visits in a 
secure place that only certain people can access for the purposes of this study. We will only enter 
your information into computers protected by [CONTACT_634055]. Your identity on these records will be indicated by a number rather than by 
[CONTACT_138944], and the information linking these numbers with  your name [CONTACT_634079] . You can choose not to answer questions at any time. We will keep the audio 
recordings and materials from all interviews and discussions confidential and will only use study numbers or fake names. We will store the original  records, including the audio recordings, for at 
least three years after completion of the study . These records will be stored in a secure, locked 
location.  
 Your personal information may be disclosed if required by [CONTACT_2371]. Fo r example, if we learn something 
that would immediately put you or others in danger, the study staff must take steps to keep you and others safe. This means that we have to share any information with the authorities (hospi[INVESTIGATOR_307], police, or social services) t hat tells us you may be in danger. For example, if you tell us that you 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 61 plan to hurt or kill yourself, hurt or kill someone else, or if you tell us that someone is abusing or 
neglecting you.  
 The study staff may use your personal information to verify that you are not in any other research 
studies. This study will not use your name [CONTACT_634080].  
 
[
SITES TO INSERT INFORMATION ABOUT SYSTEMS CURRENTLY IN PLACE TO ENSURE 
PARTICIPANTS ARE NOT PART OF OTHER CONFLICTING STUDIES, INCLUDING BIOMETRIC 
IDENTIFICATION SYSTEMS; SEE EXAMPLE BELOW FOR SOUTH AFRICAN SITES:  
 
In clinical studies where study products or other medical devices are being assessed, it is important that volunteers are enrolled in only one clinical study a t a time. Using more than one 
study product may lead to drug interactions and side effects that could potentially be harmful to 
your health. In addition to compromising the health of the study participant, this can affect the 
outcome of the study.   
The Bi ometric Co- Enrollment Prevention System (BCEPS) is a web- based system developed by 
[CONTACT_634056] (Information Technology) department, for the 
prevention of co- enrolment (being enrolled in more than one study at a time). It is a secure 
system that is used to ensure participant safety and study integrity, in studies where co -enrolment 
could impact both.  
 Authorized study staff enters the South African Identify number (SA ID) or SA/foreign Passport 
Number of the participant into the system to check if they are enrolled in any study within any of 
the organizations using BCEPS in South Africa. During screening for a study at an Aurum Institute 
clinic/site, the SA ID number or SA/foreign Passport Number and all fingerprints are capt ured 
onto the system. At every study follow -up visit thereafter, their SA ID number or SA/foreign 
Passport Number and fingerprints will be checked.  
 In the long term, after study completion, it is important that study staff can verify what studies a 
partic ipant has volunteered in, in order to ensure that the participant’s safety is not compromised 
in future study participation. The SA ID number or SA/foreign Passport Number and fingerprints 
will remain in the database on an ongoing basis for a period of up to 15 years after the end of a 
study. If the participant has not participated in any additional studies for the 15 -year period, their 
SA ID number or SA/foreign Passport Number and fingerprints will be removed from the system.  
  
If a participant refuses for the system to be used at the initial visit or requests to be removed 
from the system while using a study product, the study investigator will decide if it is safe for the 
participant to be enrolled into the study or if it is safe to  continue using study product without 
regularly checking for co- enrolment. The study that the potential participant is screening for may 
also prohibit co- enrolment in which case we will not be able to screen you.] 
 Your records may be reviewed by:  
• Represen tatives of the US Federal Government, including US OHRP, [LOCATION_003]ID and/or [LOCATION_003]ID 
contractors, and other US, local or international regulatory authorities  
• [
SITES TO INSERT APPLICABLE LOCAL AND NATIONAL AUTHORITIES ] 
• Representatives of Pi[INVESTIGATOR_32887]/MWRIF  
• MATRIX representatives  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 62 • Study m onitors  
• Site IRB/ IEC 
• Study staff  
 
[US SITE TO INCLUDE/AMEND THE FOLLOWING:  Federal and state laws and the federal medical 
Privacy Rule also protect your privacy. By [CONTACT_3368] , you provide your authorization for 
the use and di sclosure of information protected by [CONTACT_133326]  (HIPAA) Privacy Rule . This includes things learned from the procedures 
described in this consent form. Study staff may also collect other information including your name, 
address, date of birth, and information from your medical records. ]  
 [
NON-US SITES TO INCLUDE/AMEND THE FO LLOWING:  As part of your participation in this 
research study, your personal information may be sent to the [LOCATION_002] for analysis or storage. This includes things learned from the procedures described in this consent form. Study 
staff may also collect other information including your name, address, date of birth, and 
information from your medical records.  There are laws in the U.S. to protect your personal 
information when in that country. ] 
 [
SOUTH AFRICA SITES TO INCLUDE/AMEND THE FOLLOWING : The Protection of Personal 
Information Act (POPIA) ensures that all South African institutions collect, process, store, and share your personal information in a responsible manner and t hat they will be  held accountable 
should they abuse or compromise your personal information. ] 
 People outside the study team may need to see or receive your information for this study, such 
as those listed above. We cannot do this study without your authorization to use and give out 
your information to them . You do not have to give us this authorization. If you do not, then you 
may not join this study.  
 The use and disclosure of your information has no time limit. You may cancel your authorization 
to use and disclose your information at any time by [CONTACT_353492] [INVESTIGATOR_633974].  If you do cancel your authorization to use and disclose your information, your 
part in this study will end and no further information about you will be collected. Your cancellation 
would not affect information already collected in the study, or information we disclosed before you wrote to the Principal Investigator [INVESTIGATOR_633975] . 
 RESEARCH -RELATED INJURY 
[
SITES TO INCLUDE/AMMEND PER THEIR INSTITUTIONAL POLICY:  It is unlikely that you will be 
injured by [CONTACT_55825]. If you are injured or get sick from being in this study, please tell 
study staff immediately.  
 
If you believe that the research procedures have resulted in an injury to you, immediately contact 
[CONTACT_079] [INVESTIGATOR_493790]. If you become ill or injured 
as a result of participation in this study, medical treatment for the adverse reaction or injury will be provided appro priately.  The site staff will refer you for ongoing treatment for the injury, if 
needed. Clinical trial insurance purchased by [CONTACT_634057]. A n HIV infection that 
occurs during the course of the trial will not be considered an injury or illness caused by [CONTACT_634058] -002, Version 1.0          24 May 2023 63 participation. The research center or sponsor is not responsible for any loss, injuries and/or 
damages that are caused by [CONTACT_634059]:  
• Any injury that happens because you used other medicine during the study that you did not tell us about . 
• Any injury that happens because you did not follow instructions given by [CONTACT_634060] . 
• Any injury that happens because of negligence on your part.] 
 [
SITES TO SPECIFY ANY ADDITIONAL POLICY  RELATED TO EMERGENCY MEDICAL ATTENTION ]  
 
[US SITE TO INCLUDE/AMEND THE FOLLOWING:  To pay these medical expenses, Pi[INVESTIGATOR_32887]/MWRIF 
will need to know some information about you, like your name, date of birth, and social security 
number or Medicare Health Insurance Claim Number. This is because the y have to check to see 
if you receive Medicare and if you do, report the payment it makes  to Medicare. ] 
 You are not giving up any legal rights by [CONTACT_3368].  
 
CLINICALTRIALS.GOV  
A description of this research study will be available on https://www.ClinicalTrials.gov, as  required 
by U.S. law. This web site will not include information that can identify you. At most, the web site 
will include a summary of the results. You can search this website at any time.  
 
[
SOUTH AFRICA SITES TO INCLUDE LANGUAGE RELATED TO SOUTH AFRICAN NATIONAL 
CLINICAL TRIALS REGISTER ] 
 YOUR RIGHTS AS A RESEARCH PARTICIPANT /VOLUNTEER 
[
SITES TO SPECIFY INSTITUTIONAL POLICY: ] Being in this study is completely voluntary. You 
may choose not to join this study or leave this study at any time. If you choose not to join or to 
leave the study, you can still join other studies and you can still access non -study services you 
would no rmally get at this or another clinic. If you leave the study, your specimens will be 
destroyed when all protocol -specified testing has been completed and your study records may  be 
kept for at least three years after study completion.  If you want the results of the study after it 
is over, let the study staff members know.  
 PROBLEMS OR QUESTIONS 
If you ever have any questions about the study, or if you have a research -related injury, you 
should contact [
INSERT NAME [CONTACT_634081] ] at [ INSERT 
TELEPHONE NUMBER AND/OR PHYSICAL ADDRESS ]. 
 If you have questions about your rights as a research participant, you should contact [
INSERT 
NAME [CONTACT_634082]/EC OR OTHER ORGANIZATION APPROPRIATE FOR 
THE SITE ] at [INSERT PHYSICAL ADDRESS AND TELEPHONE NUMBER ]. 
  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 64 [SITES TO OMIT THE FOLLOWING IF A SEPARATE CONSENT FOR STORAGE AND FUTURE 
TESTING OF SPECIMENS IS REQUIRED] 
 
CONSENT FOR LONG- TERM STORAGE AND FUTURE TESTING OF SPECIMENS and 
RELATED HEALTH INFORMATION  
 There might be a small amount of blood  or genital samples  left over after we have done all of 
the study- related testing. We would like to ask your permission to store these leftover samples 
and related health information for use in future studies, such as future research to fight HIV and other related diseases. This health information may include personal facts about you such as your 
race, ethnicity, sex, medical conditions and your age range. This health information will not include your name [CONTACT_634083]. The samples will be stored by [CONTACT_634061].  
 If you enroll in the study and agree, your samples and related health data will be stored safely 
and securely at facilities that are designed so that only approved researchers will have access to 
the samples. Some employees of the facilities will need to have access to your samples to store 
them and keep track of where they are, but these people will not have information that directly identifies you.   
 
There is no time  limit on how long your samples will be stored.  Your samples may be shipped 
and/or stored outside of the country.  The type of testing planned for your leftover specimens is 
not yet known. However, samples may be used by [CONTACT_25715][INVESTIGATOR_32887]/MWRIF  to complete additional quality 
assurance testing, ensuring that the tests work correctly and supply accurate data. No genetic 
testing on ei ther a limited set or the full set of genes is planned for leftover samples that are 
stored for the purposes of future research. It is important that you know that any future testing 
or studies planned for these specimens must be approved by [CONTACT_625144]. You will not receive the results from any future testing of these specimens.   
 You can still enroll in this study if you decide not to have leftover samples stored for 
future studies.  If you do not want the leftove r samples stored, we will destroy them 
when all protocol -specified testing has been completed. You can withdraw your 
consent for the storage and future testing of specimens at any time by [CONTACT_625145].  However, researchers will not 
be able to destroy samples or information from research that is already underway.  
 
 
 
_______________  I DO agree to allow my biological specimens and health data to be  
Initials and Date          stored and used in future research studies.  I understand my biological  
  specimens may be shipped  and stored outside of the country.  
  
  _______________  I DO NOT agree to allow my biological specimens and health data  
Initials and Date          to be stored and used in future research studies.   
   
 
 
 
MATRIX -002, Version 1.0          24 May 2023 65 [SITES TO OMIT THE FOLLOWING IF A SEPARATE CONSENT IS REQUIRED  FOR PARTICIPANT 
IDI] 
 
CONSENT TO PARTICIPATE IN AN IN- DEPTH INTERVIEW  
 
We would like to ask your permission to participate in a conversation- style interview  (in-depth 
interview  or IDI) at the end of the study to gather more feedback about the placebo vaginal film.  
If you agree and are selected to participate in the IDI, trained study staff will ask you  questions 
about your experie nces using the product, about product design, packaging and delivery, and 
other topi[INVESTIGATOR_633976] . Information you provide during the IDI will not be shared 
with your partner.  The IDI may be conducted at the study site, over a secure digital pl atform, or 
an agreed upon location.  
 
The IDI is anticipated to last approximately [ADDRESS_846684] three years after completion of the study . 
 
We will reconfirm the decision you make today at later study visits should you change your mind 
about participating in the IDI . 
 You can still enroll in this study if you decide not to participate in the IDI . You can 
withdraw your consent to participate in the IDI  at any time.  
  
 
_______________  I DO agree to participate in an in -depth interview.  I understand the  
Initials and Date  interview will be recorded and notes will be taken.  
  
 
 
_______________  I DO NOT agree to participate in an in -depth interview.  
Initials and Date  
 
  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 66 [SITES TO OMIT THE FOLLOWING IF A SEPARATE CONSENT IS REQUIRED  FOR PERMISSION 
TO CONTACT [CONTACT_634062]] 
 
PERMISSION TO CONTACT [CONTACT_634063] a 
conversation -style interview (in -depth interview or IDI) at the end of the study to gather more 
feedback about the vaginal film.  
 
If both of you agree and your partner is selected to participate in the IDI, trained study staff will 
ask your partner questions about their views on the vaginal film and its characteristics and about 
your experiences using the vaginal film . This means that your  partner will be aware o f your 
participation in this  study and your use of the vaginal film  but no other information will be shared 
with your partner .  
 If you give us permission to talk to  your sexual partner, you  will be asked to [
SITES TO SPECIFY 
CONTACT [CONTACT_634047] : provide their current  contact [CONTACT_634048] / provide our contact 
[CONTACT_634049]] . 
 We will reconfirm the decision you make today at later study visits should you change your mind 
about us contact[CONTACT_634064] . 
 You can still enroll in this study if you decide not to give us permission to contact [CONTACT_634065]. You can withdraw your permission for us to contact [CONTACT_634066].  
 
 
 _______________  I DO give permission for study staff to talk to my sexual partner . I agree  
Initials and Date  to [
SITES TO SPECIFY CONTACT [CONTACT_634047] : provide current contact 
[CONTACT_634067]  / provide my partner with your contact 
[CONTACT_634068]] . 
 
 
_______________  I DO NOT give permission for study staff to talk to  my sexual partner .  
Initials and Date  
 
  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 67 [SITES TO OMIT  THE FOLLOWING IF NOT APPLICABLE ] 
 CONSENT FOR OFF -SITE VISITS  
 
If the site determines that an off -site visit is appropriate and with your permission, m embers of 
the research team at this clinic may be able to schedule off -site visits with you at your home or 
at another location as part of the study. Some of the scheduled stu dy visits and some of the study 
procedures may take place at your home or other location outside of the research clinic. For example, if you need to receive study product or to have a urine or blood sample collected
 but 
you are unable to come into the clinic . The study personnel will explain in greater detail the 
requirements of these visits (like the conditions of the place, the type of visit and the time it will take) and the procedures in -place to maintain your information in a confidential manner. 
Howev er, it is important that you know that off- site visits may eventually affect your 
confidentiality even if the study staff take precautions not to disclose the purpose of the visits.  
 We will only  conduct visits outside of the clinic  if you give us permissi on to do so. Please read 
carefully the following statement and initial and date one option. Choosing not to have study visit procedures outside of the study clinic will not affect your participation in this study. Even if you agree today, you can withdraw your consent for off- site visits at any time by [CONTACT_634069]. In addition, before each off- site visit, we 
will confirm with you that you still agree and remember today’s discussion.  
  
PARTICIPANT INITIALS  
 
______________ _______________  
Initials                            Date   
 I DO agree to have study visit procedures at a location 
other than the study clinic by [CONTACT_96937], when 
necessary.  
 
______________ _______________  
Initials                              Date 
 I DO NOT agree to have study visit procedures at a 
location other than the study clinic by [CONTACT_96937], 
when necessary.  
 
  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 68 SIGNATURE [CONTACT_1783]  
 
[INSERT SIGNATURE [CONTACT_625154] [CONTACT_30109]/ IEC:] 
All of the above has been explained to me and all of my current questions have been answered. 
I understand that I can ask questions about any aspect of this research study during the course 
of this study, and that future questions will be answered by [CONTACT_634070] . 
 
Any questions I have about my rights as a research participant will be answered by [INSERT 
LOCAL IRB /IEC INFORMATION].  
 I voluntarily agree to be in this research study. A copy of this p ermission form will be given to 
me.  
   
________________________________       
Participant’s Name (Print)       
 
 
________________________________  ______________  
Participant’s Signature    [CONTACT_1782]  
  
 ________________________________             
Study Staff’s Name [CONTACT_634084] (Print)  
     
________________________________  ______________  
Study Staff Conducting    Date 
Consent Discussion (Signature)  
 
  ________________________________       
Witness Name (Print)       
  
________________________________  ______________  
Witness Signature     [CONTACT_634085] -002, Version 1.0          24 May 2023 69 APPENDIX IV:  SAMPLE INFORMED CONSENT FORM (SEXUAL PARTNER 
SUBSET ) 
 
SAMPLE INFORMED CONSENT FORM  
 
MATRIX -002 
Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal 
Films  
 
[LOCATION_003]ID  
 
Version 1.0 
24 May 2023  
 
PRINCIPAL INVESTIGATOR: [SITES TO INSERT ] 
INSTITUTION: [SITES TO INSERT ] 
AFTER HOURS CONTACT [CONTACT_359242]: [SITES TO INSERT ] 
STUDY SITE CONTACT [CONTACT_359242]: [SITES TO INSERT ] 
SHORT TITLE: VALUE Placebo Film Study  
 INFORMED CONSENT  
[
SITES TO INSERT APPROPRIATE GREETING ] You are being invited  to take part in this research 
study because you were identified by a MATRIX -002 study participant as their sexual partner . 
MATRIX -002 is looking at two placebo vaginal films. Up to 30  sexual partners  of MATRIX -002 
participants like you will take part in this study across sites in the [LOCATION_002] (US), Kenya, South 
Africa, and Zimbabwe . 
 This study is sponsored by [CONTACT_634042]  ([LOCATION_003]ID) and conducted 
by [CONTACT_32928][INVESTIGATOR_9109]/Magee-Womens Research Institute and Foundation (Pi[INVESTIGATOR_32887]/MWRIF)  
as part of MATRIX: A [LOCATION_003]ID Project to Advance the Research and Development of Innovative 
HIV Prevention Products for Women. At this site, the person in charge of this study is [
SITES TO 
INSERT ]. 
 KEY INFORMAT ION 
• There are no study products (investigational drugs or other products) for you to use in this research study .  
• The purpose of including sexual partners in this study is to better understand your views 
about  the vaginal film and its characteristics, and your views on your partner’s experiences 
using the vaginal film . 
• If you qualify and choose to participate, you will be enrolled in the study and asked to complete one conversation -style interview ( in-depth int erview ) with trained study staff. The 
total length of your participation in the study will be one visit of approximately [
SITES TO 
SPECIFY TIMEFRAME ].   
• Some risks or discomforts from participating in this study include:  
o Feeling uncomfortable with some of the questions study staff may ask about your sexual behaviors and relationships . 
 
 
 
MATRIX -002, Version 1.[ADDRESS_846685] in your relationship if you or your partner are upset by [CONTACT_634071], 
contraceptive choice, or HIV prevention . 
• There may be no benefit to participating.  
• Taking part in this research study is voluntary. You do not have to participate, and you can 
stop your participation in the study at any time.  
 Please  take the time to read this entire form and ask questions before deciding to join the study. 
If you are willing to take part in the study, you will sign this form. A copy of this form will be 
offered to you. Signing this form does not mean you will be able to join the study. You must first 
complete the screening assessment  to see if you are eligible. It is important to know that your 
participation in this research study is your decision and taking part in this study is completely 
voluntary (see Your Rights as a Research Participant/Volunteer for more information).  
 WHY IS THIS RESEARCH BEING DONE?  
Investigators are studying products that women can use for HIV prevention. Vaginal films are 
being evaluated as one potential way to deliver anti -HIV drugs into the vagina (in future studies).  
The MATRIX -002 study involves two  placebo vaginal films  (contain ing no medication) . The 
components of both placebo films used in this study have been used in other products and /or 
have been generally regarded as  safe. 
 
The main goal of including sexual partners  like you  in this study is to better understand your 
views about the vaginal film and its characteristics, and your views on your partner’s experiences 
using the vaginal film  during the study. 
 WHO WILL BE IN THIS RESEARCH STUDY?  
Up to 30 sexual partners of MATRIX -002 participants  will be enrolled in the study across various sites 
in the [LOCATION_002] (US), Kenya, South Africa, and Zimbabwe . 
 DO I HAVE TO BE IN THIS STUDY?  
You do not have to be in this study. You can still get the care you need even if you do not join the study.  
 
WHAT WILL I BE ASKED TO DO IF I JOIN THIS RESEARCH STUDY?   
You will be asked to participate in an in -depth interview (IDI) with trained study staff. You will 
be asked about your
 attitudes towards and experiences with the vaginal film, and your perspective 
of your partner’s attitudes and experiences  with the vaginal film.  
 
WHAT WILL HAPPEN DURING THE STUDY VISIT?  
The study consists of one study visit, which will take place after you sig n this informed consent 
form. If you agree and are eligible to participate, the IDI may take place today. If scheduling 
does not allow , it may take place on a different day that is convenient for you. Additional visit(s) 
may be conducted to complete all required procedures, if necessary. The visit  will take place at a 
place agreed upon by [CONTACT_634072], which may be the study clinic, your home, or 
another convenient location [SITE TO INCLUDE ALTERNATE LOCATION] . 
 
The procedures done at this visit will take about [SITES TO SPECIFY TIMEFRAME] .  
• Study staff will ask you where you live and other questions about you, and your understanding of the study requirements . 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 71 • In the IDI, you will be asked questions about: 
o Your a ge, education level, health, relationship status, and employment status.  
o Your views about HIV risk and prevention, sexual history, existing prevention methods, and aspects of your relationship. 
o Your views about  the vaginal film  and your partner’s experienc es using the vaginal 
film. 
• The IDI will be performed  [
SITES TO SPECIFY MECHANISM:  in the presence of one or 
two M ATRIX -002 research staff members  / remotely by a behavioral researcher]. The IDI 
will take approximately [ SITES TO SPECIFY TIMEFRAME ].  
o Study staff will make every effort to ensure your privacy and confidentiality. Information you provide during the IDI will not be shared with your partner.  
o During the IDI, the interviewer may take notes. Interviews will be audio- recorded to 
make sure we re cord your words exactly how you said them.  
• In addition, study staff will:  
o Reimburse you for your visit.  
o Inform you about other available health and social services, if needed. 
o Schedule your next visit, if necessary. 
 
RISKS AND/OR DISCOMFORTS You may feel embarrassed and/or worried when talking about sexual activities, your living situation, or your opi[INVESTIGATOR_633977] . You can choose not to answer 
questions at any time. Trained study staff will help you with any feelings o r questions  you have . 
 We will make every effort to protect your privacy and confidentiality during the study visit. Your 
visit will take place in private. Reports via computer will be stored in computers that are password-
protected and will not include pe rsonal information that could identify or link information to you; 
only your study ID number will be recorded.  However, i t is possible that others may learn of your 
participation in this study, and because of this, may treat you unfairly or discriminate against you. 
If you have any problems, study staff will talk with you and try to help you.  
 
The interviews with study staff  will be audio recorded and questions of a personal nature may be 
asked. Responding to these questions may make you uncomfortable. The audio files will be put into writing by [CONTACT_634073]. You should NOT identify anyone in the interviews 
and any names that might be mentioned on the recording will only be noted in the transcript using a generic description. The audio files will be stored in computers that are password 
protected.  
 
BENEFITS 
Though you may not experience any direct benefit from participation in this study, information 
learned from this study may help us learn ways to prevent the spread of HIV in the future .
 Your 
opi[INVESTIGATOR_633978] e important to scientists working to develop this new prevention option . 
 Medical care for HIV infection and other health conditions will not be part of this study. This study cannot provide you with general medical care, but study staff
 will refer you to other available 
sources of care, if needed.   
 
 
 
 
MATRIX -002, Version 1.[ADDRESS_846686] to you for study -related  visits.  
 
REIMBURSEMENT  
[SITES TO INSERT INFORMATION ABOUT LOCAL REIMBURSEMENT: ] You will receive [ SITES TO 
INSERT AMOUNT $ XX] for your time, effort, and travel to and from the clinic to take part in the 
in-depth interview . 
 
CONFIDENTIALITY We will make every effort to keep your information priva te and confidential. But we cannot 
guarantee it.  
 The s tudy visit will take place in private. We will keep the information about your study visit in a 
secure place that only certain people can access for the purposes of this study. We will only enter your information into computers protected by [CONTACT_634074] w ill not include information that 
could identify you. Your identity on these records will be indicated by a number rather than by 
[CONTACT_138944], and the information linking these numbers with your name [CONTACT_634079] . You can ch oose not to answer questions at any tim e. We will keep the audio 
recordings and materials from all interviews and discussions confidential and will only use study 
numbers or fake names.  We will store the original  records, including the audio recordings, for at 
least three years after completion of the study . These records will be stored in a secure, locked 
location.  
 
Your personal information may be disclosed if required by [CONTACT_2371]. For example, if we learn something 
that would immediately put you or others in danger, the study staff must take steps to keep you and others safe. This means that we have to share any information with the authorities (hospi[INVESTIGATOR_307], police, or social services) that tells us you may be in danger. For example, if you tell us that you 
plan to hurt or kill yourself, hurt or kill someone else, or if you tell us that someone is abusing or 
neglecting you.  
 This study will not use your name [CONTACT_634080].  
 
Your records may be reviewed by:  
• Representatives of the US Federal Government, including US OHRP, [LOCATION_003]ID and/or [LOCATION_003]ID 
contractors, and other US, local or international regulatory authorities  
• [
SITES TO INSERT APPLICABLE LOCAL AND NATIONAL AUTHORITIES ] 
• Representatives of Pi[INVESTIGATOR_32887]/MWRIF  
• MATRIX representatives  
• Study m onitors  
• Site IRB/ IEC 
• Study staff  
 [
US SITE TO INCLUDE/AMEND THE FOLLOWING:  Federal and state laws and the federal medical 
Privacy Rule also protect your privacy. By [CONTACT_3368] , you provide your authorization for 
the use and disclosure of information protected by [CONTACT_634075] -002, Version 1.[ADDRESS_846687]  (HIPAA) Privacy Rule . This includes things learned from the procedures 
described in this consent form. Study staff may also collect other information including your name, 
address, date of birth, and information from your medical records. ]  
 
[NON-US SITES TO INCLUDE/AMEND THE FOLLOWING:  As part of your participation in this 
research study, your personal information may be sent to the [LOCATION_002] for analysis or 
storage. This includes things learned from the procedures described in this consent form. Study staff may also collect other information including your name, address, date of birth, and informati on from your medical records.  There are laws in the U.S. to protect your personal 
information when in that country. ] 
 [
SOUTH AFRICA SITES TO INCLUDE/AMEND THE FOLLOWING : The Protection of Personal 
Information Act (POPIA) ensures that all South African inst itutions collect, process, store, and 
share your personal information in a responsible manner and t hat they will be  held accountable 
should they abuse or compromise your personal information. ] 
 
People outside the study team may need to see or receive your information for this study, such 
as those listed above. We cannot do this study without your authorization to use and give out 
your information to them . You do not have to give us this authorization. If you do not, then you 
may not join this study.  
 The use and disclosure of your information has no time limit. You may cancel your authorization to use and disclose your information at any time by [CONTACT_353492] [INVESTIGATOR_633979].  If you do cancel your authorization to use and disclose your information, your 
part in this study will end and no further information about you will be collected. Your cancellation 
would not affect information already collected in the study, or information we disclosed before 
you wrote to the Princip al Investigator to cancel your authorization . 
 
RESEARCH -RELATED INJURY 
[
SITES TO INCLUDE/AMMEND PER THEIR INSTITUTIONAL POLICY:  It is unlikely that you will be 
injured by [CONTACT_55825]. If you are injured or get sick from being in this study, please tell study staff immediately.  
 
If you believe that the research procedures have resulted in an injury to you, immediately conta ct 
the Principal Investigator [INVESTIGATOR_493790]. If you become ill or injured 
as a result of participation in this study, medical treatment for the adverse reaction or injury will be provided appropriately.  The site staff will re fer you for ongoing treatment for the injury, if 
needed. Clinical trial insurance purchased by [CONTACT_634057]. An HIV infection that occurs during the course of the trial will not be considered an injury or illness caused by [CONTACT_634076]. The research center or sponsor is not responsible for any loss, injuries and/or damages that are caused by [CONTACT_634077]:  
• Any injury that happens because you used other medicine during the study that you did not tell us about . 
• Any injury that happens because you did not follow instructions given by [CONTACT_634060] . 
• Any injury that happens because of negligence on your part .] 
 
 
 
 
MATRIX -002, Version 1.0          24 May 2023 74 [SITES TO SPECIFY ANY ADDITIONAL POLICY  RELATED TO EMERGENCY MEDICAL ATTENTION ]  
 [
US SITE TO INCLUDE/AMEND THE FOLLOWING:  To pay these medical expenses, Pi[INVESTIGATOR_32887]/MWRIF 
will need to know some information about you, like your name, date of birth, and social security 
number or Medicare Health Insurance Claim Number. This is because the y have to check to see 
if you receive Medicare and if you do, report the payment it makes  to Medicare. ] 
 You are not giving up any legal rights by [CONTACT_3368].  
 
CLINICALTRIALS.GOV  
A description of this research study will be available on https://www.ClinicalTrials.gov, as  required 
by U.S. law. This web site will not include information that can identify you. At most, the web site 
will include a summary of the results. You can search this website at any time.  
 
[
SOUTH AFRICA SITES TO INCLUDE LANGUAGE RELATED TO SOUTH AFRICAN NATIONAL 
CLINICAL TRIALS REGISTER ] 
 YOUR RIGHTS AS A RESEARCH PARTICIPANT /VOLUNTEER 
[
SITES TO SPECIFY INSTITUTIONAL POLICY: ] Being in this study is completely voluntary. You 
may choose not to join this study or leave this study at any time. If you choose not to join or to 
leave the study, you can still join other studies and you can still access non -study services you 
would normally get at this clinic. If you leave the study, your study records may be kept for at 
least three years after study completion. If you want the results of the study after it is over, let 
the study staff members know.  
 
PROBLEMS OR QUESTIONS 
If you ever have any questions about the study, or if you have a research -related injury, you 
should contact [ INSERT NAME [CONTACT_634081] ] at [ INSERT 
TELEPHONE NUMBER AND/OR PHYSICAL ADDRESS ]. 
 If you have questions about your rights as a research participant, you should contact [
INSERT 
NAME [CONTACT_634082]/EC OR OTHER ORGANIZATION APPROPRIATE FOR 
THE SITE ] at [INSERT PHYSICAL ADDRESS AND TELEPHONE NUMBER ]. 
 
  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 75 SIGNATURE [CONTACT_1783]  
 
[INSERT SIGNATURE [CONTACT_625154] [CONTACT_30109]/ IEC:] 
All of the above has been explained to me and all of my current questions have been answered. 
I understand that I can ask questions about any aspect of this research study during the course 
of this study, and that future questions will be answered by [CONTACT_634070] . 
 
Any questions I have about my rights as a research participant will be answered by [INSERT 
LOCAL IRB/IEC INFORMATION].  
 I voluntarily agree to be in this research study. A copy of this p ermission form will be given to 
me.  
   
________________________________       
Participant’s Name (Print)       
 
 
________________________________  ______________  
Participant’s Signature    [CONTACT_1782]  
  
 ________________________________             
Study Staff’s Name [CONTACT_634084] (Print)  
     
________________________________  ______________  
Study Staff Conducting    Date 
Consent Discussion (Signature)  
 
  ________________________________       
Witness Name (Print)       
  
________________________________  ______________  
Witness Signature     [CONTACT_634086] -002, Version 1.0          24 May 2023 76 REFERENCES 
 
 
1. Alternative Formulations of Tenofovir and UC781.  
https://reporter.nih.gov/search/K5gvxVFx3ECPmIAo3Bt15Q/project- details/8471636 . 
Accessed February 23, 2023.  
2. F ilm Antiretrovira l Microbicide Evaluation.  
https://reporter.nih.gov/search/HcBIzL_XW0SbUQ2QIZ5krA/project- details/9707725 , 
February 23, 2023.  
3. A cceptability Study of Vaginal Films for HIV Prevention (FACE).  
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=[STUDY_ID_REMOVED]&draw=2&rank=1 . 
Accessed February 23, 2023.  
4. P atel SK, Bunge K, Downs J, Hillier S, Rohan L. Vaginal Film Administration and 
Placement Study in Women (FLAG Trial). Paper presented at: Aids Research and Human Retroviruses2018.  
5. Musara P, Milford C, S hapley -Quinn MK, et al. Preferences and Acceptability of Vaginal 
Delivery Forms for HIV Prevention Among Women, Male Partners and Key Informants in 
South Africa and Zimbabwe: Qualitative Findings. 
AIDS Behav. Jan 2021;25(1):124- 138. 
6. Nel AM, Mitchnick LB , Risha P, Muungo LT, Norick PM. Acceptability of vaginal film, soft-
gel capsule, and tablet as potential microbicide delivery methods among African women. 
J Womens Health (Larchmt). Aug 2011;20(8):1207- 1214.  
7. Guthrie KM, Fava JL, Vargas SE, et al. The R ole of Volume in the Perceptibility of Topi[INVESTIGATOR_633980]: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex. 
AIDS Res Hum Retroviruses. Dec 2020;36(12):1059- 1070.  
8. Guthrie KM, Rohan L, Rosen RK, et al. Vaginal film for prevention of HIV: using visual 
and tactile evaluations among potential users to inform product design. Pharm Dev 
Technol. Mar 2018;23(3):[ADDRESS_846688]. Apr 15 2016;71(5):498- 505. 
10. Robinson JA, Marzinke MA, Bakshi RP, et al. Comparison of Dapi[INVESTIGATOR_633981] (FAME 02B). AIDS Res Hum 
Retroviruses. Apr 2017;33(4):339- 346. 
11. Politch JA, Cu -Uvin S, Moench TR, et al. Safety, acceptability, and pharmacokinetics of a 
monoclonal antibody- based vaginal multipurpose prevention film (MB66): A Phase I 
randomized trial. PLoS Med. Feb 2021;18(2):e1003495.  
12. Bunge KE, Dezzutti CS, Hendrix CW, et al. FAME -04: A Phase 1 trial to assess the safety, 
acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir. 
J Int AIDS Soc. Aug 2018;21(8):e25156.  
13. Robinson JA, Marzinke MA, Fuchs EJ, et al. Comparison of the Pharmacokinetics and Pharmacodynamics of Single -Dose Tenofovir Vaginal Film and Gel Formulation (FAME 
05). 
J Acquir Immune Defic Syndr. Feb 1 2018;77(2):175- 182. 
14. A Study of the Safety and Acceptability of a Placebo Vaginal Film: FAME101 (FAME101).  
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=[STUDY_ID_REMOVED]&draw=2&rank=1 . 
Accessed February 23, 2023.  
15. Saf ety and Pharmacokinetics of Two Vaginal Film Formulations Containing the Integrase 
Inhibitor MK -2048 (FAME103).  
 
 
 
MATRIX -002, Version 1.0          24 May 2023 77 https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=[STUDY_ID_REMOVED]&draw=2&rank=1 . 
Accessed February 23, 2023.  
16. R andomized Cross -Over Study of Self- Insertion of Two Placebo Vaginal Film 
Formulations (FAME103B).  
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=[STUDY_ID_REMOVED]&draw=2&rank=1 . 
Accessed February 23, 2023.  
17. L ong Acting Film Technology for Contraception and HIV Prevention (LATCH).  
https://reporter.nih.gov/search/qr4MiFnYsk- QCMp1Zy3Xzw/project -details/10580096 . 
Accessed February 23, 2023.  
18. S ekhon M, Cartwright M, Francis JJ. Acceptabili ty of healthcare interventions: an 
overview of reviews and development of a theoretical framework. BMC Health Services 
Research. 2017/01/26 2017;17(1):88.  
19. Ortblad KF, Sekhon M, Wang L, et al. Acceptability Assessment in HIV Prevention and Treatment Int ervention and Service Delivery Research: A Systematic Review and 
Qualitative Analysis. 
AIDS Behav. Jul 23 2022.  
20. Doggett EG, Lanham M, Wilcher R, Gafos M, Karim QA, Heise L. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations 
for gender -sensitive microbicide introduction. 
J Int AIDS Soc. 2015;18(1):[ZIP_CODE].  
21. Denzin NK, Lincoln YS. Handbook of qualitative research . 2nd ed. Thousand Oaks, Calif.: 
Sage Publications; 2000.  
22. Miles MB, Huberman AM. Qualitative data analysis: An expanded sourcebook, 2nd ed . 
Thousand Oaks, CA, US: Sage Publications, Inc; 1994.  
23. Macqueen K, McLellan -Lemal E, Bartholow K, Milstein B. Team -based codebook 
development: Structure, process, and agree ment. Handbook for Team -Based Qualitative 
Research. 01/01 2008:119- 135. 
24. Hughes R. Considering the Vignette Technique and its Application to a Study of Drug 
Injecting and HIV Risk and Safer Behaviour. Sociology of Health & Illness. 
1998;20(3):381 -400. 
 
 